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Abstract 
The most crucial limitation in diagnosis and treatment of the tumor brain is the unique and 
complicated environment imposed by the central nervous system barriers, mainly due to 
blood-brain barrier. It can be said that blood-brain barrier is a sort of sanctuary site with 
unique structural and biochemical properties. In the last decades, nanotechnology has been 
studied to solve this problem, since nanoparticles present a small size and a large surface 
area which improves the characteristics of drugs. Specifically, in drug encapsulation and in 
functionalization for a speciﬁc target which minimizes unwanted eﬀects and maximize 
therapeutic eﬀects. 
Therefore, the development of a faithful in vitro cell system, which would reﬂect as many 
relevant in vivo BBB properties as possible, it is an important ﬁrst step in the evaluation of 
new drugs and new drug delivery systems to cross this barrier. Here, it is purpose a human 
cell model of the blood brain barrier for use as tool for screening nanoparticles interactions, 
with emphasis to camptothecin loaded in solid lipid nanoparticles.  
In this system, a triple co-culture was established. Endothelial cells were grown in the luminal 
side of the semi-permeable filter, astrocytes on the inverted side of the insert and a glioma 
cell line on the bottom of the abluminal side. First, permeability to three different well-
known compound showed that endothelial monolayer, besides the lower trans-endothelial 
electrical resistance values, mimic a highly restrictive barrier. Also, immunocytochemistry 
and scanning electron images showed a confluent endothelial monolayer at 7th day and 
4,6x104 cells/cm2 initial concentration. On the same day, astrocytes were co-cultured and on 
2nd a glioma cell line at the same endothelial cell proportion was added. When glioma cell 
line was added to the in vitro model, endothelial cells co-cultured with astrocytes, it is clear 
the barrier disruption, by decreasing of trans-endothelial electrical resistance values and for 
scanning electron images it is possible analyze the loss of tight junctions. Finally, the addition 
of astrocytes is inconclusive because of cellular concentration limitation, however the 
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astrocytes on scanning electron images seems can influence endothelial monolayer by 
mechanical forces.  
In parallel, it were developed camptothecin loaded in solid lipid nanoparticles as an anti-
cancer model drug. The pharmacokinetic properties of camptothecin are not favorable to its 
free administration, since the compound has low water solubility and is chemically unstable, 
only at acidic pH has anti-cancer activity. So, incorporation of camptothecin within the 
hydrophobic matrix is essential to protect the drug from degradation, to increase the 
therapeutic effect.   
The work done before for our group it was accurate and it was established new conditions to 
produce and characterize these nanoparticles. Solid lipid nanoparticles loaded with 
camptothecin were produced and characterized. The size around 200 nm, the charge slightly 
negative and association efficiency values are suitable for cell membrane passage and uptake 
under normal physiological conditions. Then, the nanoparticles were tested on the three 
different cells used on the in vitro model. Camptothecin loaded in solid lipid nanoparticles 
consistently showed higher potency as compared to the free camptothecin and low 
cytotoxicity. Also, it showed more biocompability with endothelial cells that with the 
astrocytoma cell line.  
Therefore, it is necessary analyze nanoparticles permeation on the in vitro model and 
compare those results with the in vivo. However, it is expected that the triple co-culture 
model purposed is a good alternative to screening nanoparticles formulations and can be a 
new insight to study blood brain barrier structure and mechanisms. 
Keywords:  In vitro model, Blood-brain barrier, Camptothecin, Glioma 
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Resumo 
A baixa eficácia no diagnóstico e no tratamento do tumor cerebral tem como principal razão 
os complexos mecanismos presentes no sistema nervoso central, especificamente presentes 
na barreira hemato-encefálica. Atravessar esta barreira torna-se numa tarefa quase 
impossível principalmente devido às células presentes e aos fatores químicos e biológicos 
envolvidos. Recentemente, a nanotecnologia tem sido uma área de investigação de grande 
interesse, uma vez que as nanopartículas apresentam um tamanho reduzido e uma grande 
área superfície-volume, o que pode melhorar a eficácia terapêutica.  
Desta forma, o desenvolvimento de um sistema celular in vitro, que apresente o maior 
número de propriedades in vivo, sem dúvida é o primeiro passo para a avaliação de novos 
medicamentos que necessitam de atravessar a barreira hemato-encefálica. Com o objetivo de 
aumentar a compreensão das interações presentes nesta barreira e os efeitos das células 
cerebrais com as nanopartículas é proposto o desenvolvimento de um modelo celular humano 
da barreira hemato-encefálica e o estudo da camptotecina encapsulada em nanopartículas 
lipídicas sólidas.   
Neste modelo, um sistema de tripla co cultura é estabelecido. As células endoteliais foram 
colocadas no lado apical da membrana, os astrócitos no lado contrário da membrana no lado 
basolateral e o glioma no fundo da placa também no lado basolateral. Estudos de 
permeabilidade com três diferentes moléculas demonstram que a monocamada endotelial, 
apesar dos baixos valores de resistência elétrica trans endotelial, consegue mimetizar uma 
barreira selectiva como acontece na situação in vivo. Também, as imagens de 
imunocitoquímica e de microscopia electrónica é possível observar uma monocamada 
confluente ao sétimo dia e com uma concentração inicial de 4,6x104 cells/cm2. Quando, a 
linha cellular de glioma é adicionada ao modelo torna-se clara a disrupção da barreira pela 
dimuição dos valores de resistência elétrica trans endotelial e pelas imagens de microscopia 
electrónica onde é possível observar a perda das ligações características das células 
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endoteliais. Por último, aquando da adição dos astrócitos os resultados foram inconclusivos 
devido à limitação celular das células primários, porém através da microscopia electrónica 
torna-se evidente uma influência mecânica dos astrócitos com as células endoteliais.  
Em paralelo foram desenvolvidas nanopartículas incorporados com camptotecina como 
fármaco anti-cancerígena modelo.  As propriedades farmacocinéticas da camptotecina não 
são favoráveis à sua administração em fármaco livre, uma vez que o fármaco apresenta uma 
baixa soubilidade em água e apresenta uma estrutura química instável, só a pH ácido é que 
apresenta actividade anti-cancerígena. Desta forma, a incorporação do fármaco numa matriz 
hidrofóbica é essencial para proteger a camptotecina da degradação e assim aumentar a 
eficácia terapêutica.  
O trabalho desenvolvido anteriormente pelo nosso grupo com este fármaco foi melhorado e 
novas condições de produção e caracterização foram desenvolvidas. As nanopartículas com o 
fármaco incorporado apresentaram tamanhos cerca dos 200nm e carga ligeiramente negativa, 
o que está de acordo com passage da membrane cellular e a incorporação em condições 
fisiológicas normais. Posteriormente, as nanopartículas foram testadas nas células usados no 
modelo cellular. As nanopartículas sem fármaco em todas as condições apresentam baixa 
citotoxicidade. Por outro lado, a camptotecina livre apresenta a citotoxicidade mais elevada 
em todas as condições. A camptotecina incorporada nas nanopartículas apresenta uma maior 
eficácia em comparação com o fármaco livre, e apresenta uma maior biocompatibilidade nas 
células endoteliais do que com a linha celular de glioma.   
Assim sendo, é necessário analisar a permeabilidade das nanopartículas no modelo in vitro e 
comparar os resultados com modelos in vivo. Porém, é esperado que o modelo proposto é 
uma boa alternativa para avaliar novos fármacos incorporados em diferentes sistemas e pode 
ser uma nova estratégia para estudar a estrutura e mecanismos associados à barreira hemato-
encefálica.  
Palavras-chave:  Modelo in vitro, Barreira hemato-encefálica, Camptotecina, Glioma 
  
  
 
xi 
 
Contents 
Chapter 1 ........................................................................................... 1 
Introduction ....................................................................................................... 1 
1. Blood Brain Barrier ........................................................................................ 2 
2. Transports across the BBB ............................................................................... 5 
3. Drug targeting to the brain ............................................................................ 10 
4. BBB models ............................................................................................... 13 
Chapter 2 .......................................................................................... 19 
Aim... ............................................................................................................ 19 
Chapter 3 .......................................................................................... 21 
Materials & Methods ........................................................................................... 21 
Materials ..................................................................................................... 21 
Methods ...................................................................................................... 22 
3.1. Cell Culture ............................................................................................ 22 
3.2 In vitro models ......................................................................................... 24 
3.3 Camptothecin loaded Solid Lipid Nanoparticles .................................................. 31 
3.4. In vitro studies ........................................................................................ 35 
Chapter 4 .......................................................................................... 37 
Results & Discussion ........................................................................................... 37 
4.1. Characterization of the in vitro mouse model .................................................. 38 
4.2. Characterization of the in vitro human BBB model on monoculture ........................ 39 
4.3. The influence of different cells on the in vitro BBB model ................................... 45 
4.4. Nanoparticles characterization .................................................................... 52 
4.5. In vitro studies ....................................................................................... 54 
Chapter 5 .......................................................................................... 57 
Conclusion ....................................................................................................... 57 
Chapter 6 .......................................................................................... 59 
Future work ..................................................................................................... 59 
References ........................................................................................ 61 
  
 
 
  
xiii 
 
List of Figures  
Figure 1.1 The cell associations at the BBB [5].. ......................................................... 3 
Figure 1.2 Simplified explanation of the molecular composition of endothelial TJ at the 
BBB are shown [17].. ................................................................................... 4 
Figure 1.3 Different type of blood brain barrier (BBB) transporters adapted from [8]... ........ 5 
Figure 1.4 Mechanisms of transport across BBB [2].. .................................................... 9 
Figure 1.5 Overview of different strategies for brain targeting of drugs adapted from [23]. . 10 
Figure 3.1 Schematic illustration of [A] in vitro BBB model and [B] in vivo BBB.. ............... 24 
Figure 3.2 The experimental procedure for monoculturing the bEnd3 cell line. ................. 25 
Figure 3.3 The experimental procedure for monoculturing the endothelial cells.. ............. 26 
Figure 3.4 The experimental procedure for co-culturing the endothelial cells and U87 cell 
line.. ..................................................................................................... 26 
Figure 3.5 The experimental procedure for coculturing the endothelial cells and 
astrocytes on different sides of the semi permeable ﬁlter.. .................................. 27 
Figure 3.6 The experimental procedure for co-culturing the endothelial cells, astrocytes 
and U87 cell line on different sides of the semi permeable ﬁlter.. .......................... 28 
Figure 3.7 Schematic representation of SLN production by high shear homogenisation 
followed by ultrasonication adapted from[40]. .................................................. 32 
Figure 4.1 TEER measurements in different cell mouuse densities on monoculture.. .......... 38 
Figure 4.2 TEER measurements in different cell human densities on monoculture.............. 39 
Figure 4.5 Cellular gate and fluorescence histogram from hCMEC/D3 flow cytometry 
experiment using VE-Cadherin-FITC.. ............................................................. 42 
Figure 4.7 Permeability assay.. ........................................................................... 44 
Figure 4.8 TEER measurements in co-culture, endothelial cells and U87 cell line. ............. 46 
Figure 4.9 TEER measurements in co-culture, endothelial cells and primary astrocytes 
cells.. .................................................................................................... 46 
 xiv 
 
 
 
Figure 4.10 TEER measurements in endothelial cells cultured with U87 cell line and 
primary astrocytes cells.. ........................................................................... 47 
Figure 4.11 Permeability assay on 7th day. Permeability experiment using the FD4 
molecule.. .............................................................................................. 47 
Figure 4.12 Fluorescence histogram from hCMEC/D3 co-cultured with U87 cell line using 
VE-Cadherin-FITC.. ................................................................................... 49 
Figure 4.13 SEM images of surface endothelial cells co-cultured with astrocytes and U87 
cell line on 7th day.. .................................................................................. 49 
Figure 4.14 SEM images of endothelial cells surface co cultured with astrocytes and U87 
cell line in on 7th day.. ............................................................................... 50 
Figure 4.15  SEM images of endothelial cells, astrocytes and U87 cell line in culture on 7th 
day.. ..................................................................................................... 51 
Figure 4.16 Volume density (%) analysis of Empty and CPT-loaded SLN particle size.. ......... 52 
Figure 4.17 Calibration curve to extrapolate CPT concentration values using HPLC 
method. ................................................................................................. 53 
Figure 4.18 Reduction of Alarmar blue reagent on endothelial cells, on glioma cells and 
primary astrocytes.. .................................................................................. 54 
Figure 4.19 Cellular viability of hCMEC/D3, human astrocytes and U87 cell line using the 
Alamar Blue Cell Viability Assay Reagent.. ...................................................... 55 
 
 
 
 
 
 
 
 
 
  
xv 
 
Acronyms 
ABC  Adenosine triphosphate-Binding Cassete 
AET  Active Eﬄux Transporter 
AMT  Absorptive-Mediated Trancytosis 
BBB  Blood-Brain Barrier 
BCRP  Breast Cancer Resistance Protein 
bEnd3 Immortalized mouse Endothelial cells 
bFGF  basic Fibroblast Growth Factor 
BSA Bovine Serum Albumin  
CMT  Carrier-Mediated Transport 
CNS  Central Nervous System 
CPT Camptothecin  
CPT-SLN  Camptothecin-loaded SLN  
DIV-BBB  Dynamic In vitro Blood-Brain Barrier 
DLS Dynamic Light Scattering 
DMEM Dulbecco’s Modified Eagle’s Medium  
DMSO DimethylSulfOxide 
DPBS Dulbecco’s Phosphate Buffered Saline 
EC Endothelial Cells  
EDTA EthyleneDiamineTetraacetic Acid 
FBS Fetal Bovine Serum  
FD Fluorescein isothiocyanate – Dextran  
hCMEC/D3  human Capillary Endothelial cells 
HPLC  High Performance Liquid Chromatography  
HPLC High Performance Liquid Chromatography 
JAMS Junctional Adhesion Molecules 
MDR  Multidrug Resistance Proteins 
MRP  Multidrug Resistance-associated Proteins 
NVU  NeuroVascular Unit  
P-gp P-glycoprotein  
 xvi 
 
 
 
RMT  Receptor-Mediated Transcytosis 
SEM Scanning Electron Microscopy  
SLN Solid Lipid Nanoparticles 
TEER Trans-Endothelial Electrical Resistance  
TJ Tight Junctions   
WGA Wheat Germ Agglutinin 
ZO Zonula Occludens  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1 
 
Chapter 1  
Introduction 
The most crucial limitation in diagnosis and treatment of the neuronal diseases is the unique 
and highly controlled microenvironment of the Central Nervous System (CNS) barriers [1-4]. 
There are three key interfaces at which cells form barriers between the blood and the CNS, 
namely the Blood-Brain Barrier (BBB), blood cerebrospinal fluid barrier and the arachnoid 
barrier [5], being BBB the most important. This interface is formed by specialized endothelial 
cells (EC) in close association with basement membrane and neighboring cell types within the 
neurovascular unit [6]. The microvascular endothelium at the BBB is characterized by the 
presence of tight junctions between adjacent EC, lack of fenestrations, and minimal 
pinocytotic vesicles [7]. 
Besides the delivery of drugs to CNS through BBB being really poor and the treatment 
inefficient, the drugs used present many limitations such as side effects and bioavailabitity. 
Therefore, it is necessary to develop drug carriers to improve the effects in diagnostics, 
therapy and theragnostics [8]. The development of a close in vitro cell system is a difficult 
task and an important first step in the evaluation of new drugs and drug delivery systems to 
cross the BBB [9]. However, at present, no in vitro model can faithfully reproduce all the 
properties and characteristics of the in vivo BBB model.  
This chapter will focus on BBB structure and mechanisms. Firstly, its importance functional 
and morphological it will be analyzed. A brief description of the different types of 
transporters it will be discussed, as the different techniques to perform brain drug targeting 
and the current strategies. Finally, it will be present various in vitro models divided into 
static and dynamic ones. 
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1. Blood Brain Barrier 
In 1885, more than 120 years ago, Paul Ehrlich was the first to demonstrate the presence of 
a barrier between blood and brain. He found that intravenously injected dyes, rapidly 
contrast all organs except the brain [10]. A few years later, his student Edwin Goldman 
made other experience where he injected these dyes into the cerebrospinal fluid. He found 
that this route had free access to neural tissue, however not of the peripheral organs. So, 
these dyes were prevented from directly entering the blood supply of the brain [2]. Since 
this crucial discovery, our understanding of the BBB molecular structure, physiological 
processes and our knowledge in its transporters increased [1].  
BBB is regarded as an active, dynamic and extremely complex interface between the blood 
and the CNS which has specific structural and biochemical properties [9]. It is clear that 
BBB is very important in the protection of neurons from fluctuations in the plasma 
component and it was the main factor that leads to its development. This interface controls 
the rate of influx and efflux of biological substances needed for the brain metabolic 
processes and neuronal function. Because, of its selectivity, the BBB plays a crucial role to 
regulate the trafficking between blood and CNS and the determination of neuroimmunology 
and neuropathology [11]. So, BBB provides protection against many toxic compounds and 
pathogens. For this reason, it is of paramount importance in regulating the constancy of the 
brain internal environment [9]. It also contributes to ion homeostasis function which keeps 
the ionic composition optimal for synaptic signaling and preserves neural connectivity. It 
allows immune surveillance and responses to minimal inflammation and cell damage [5, 12]. 
Morphologically, the BBB is formed by specialized EC, paving the luminal side (the blood 
capillary side) in close association with basement membrane and neighboring cell types, 
which include perivascular pericytes, astrocytes, neurons and microglia in the abluminal 
membrane. These various cell types and basal lamina collectively constitute the 
neurovascular unit (NVU), Figure 1 [13]. Other important characteristic of in vivo BBB is the 
shear stress over the surface of the cells which is a tangential force generated by the blood 
flow [14]. Shear stress promotes the differentiation process and maintenance of BBB 
phenotype [15]. 
Specifically, the basement membrane of the cerebral endothelium is constituted by three 
apposed layers, made of different types of extracellular matrix classes of molecules such as 
collagen IV [16], glycoproteins, proteoglycans, laminin and various types of matrix adhesion 
receptors. In adults his membrane is about 30-40 nm thick and separates ECs and pericytes 
from the surrounding extracellular space [17]. Their interconnections produce a complex 
matrix which anchors cells and establishes the support for neighboring cells [18]. Also, the 
neighboring cells play an important role improving the barrier functions. It is a fact that ECs 
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are the major cellular constituent of the brain. The principal features associated with BBB 
ECs which differ these cells from the other ones in the rest of the body are the lack of 
fenestrations, low level of pinocytic vesicles, a high mitochondrial content, the presence of 
more extensive tight junctions (TJ) with electrical resistance as high as 8000 Ohmcm2 and 
the expression of various transporters that influence molecule transport to the brain [19]. 
Concerning to astrocytes, they constitute nearly half of brain cells [20] and encircle 90% of 
the BBB endothelium on the abluminal side. Astrocytes have a key feature on the induction 
and maintenance of BBB integrity, namely by the secretion of factors such as transforming 
growth factor-β, glial-derived neurotrophic factor, basic fibroblast growth factor (bFGF) and 
angiopoetin 1 into the medium;  alter the expression of drug transporters such as P-
glycoprotein (P-gp) and induce tighter TJ [21]. Although this importance has been 
documented since two decades, the molecular pathways still remains unclear [5, 18]. As 
referred to pericytes, also known as vascular smooth muscle cells, they have a physical 
association with the endothelium. The release of ECs factors can induce migration of 
pericytes and affect the maintenance of the integrity of the vessel. Pericytes are able to 
control the capillary diameter, due to their contractile characteristics, then modulate the 
cerebral blood flow [22]. Regarding to microglia cells, the exact mechanisms of how 
microglia influences BBB properties are still unknown, however it is clear that they are 
playing an important role in immune response and consequently in the BBB integrity [22]. So 
far, very few are known about the precise role that neurons play on the BBB phenotype. 
Although, there are some evidence that neurons affect cerebral blood flow and can regulate 
the function of blood vessels [7]. 
 
Figure 1.1 The cell associations at the BBB [5]. The NVU is a complex cellular system that 
includes highly specialized endothelial cells, a high concentration of pericytes embedded in 
the endothelial cell basement membrane; astrocytic endfeet associated parenchymal 
basement membrane, neurons and immune cells. Considering all cellular interactions 
presents on neurovascular unit, it can be said that BBB presents unique structural and 
biochemical properties. 
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TJ consist of an extreme complex of integral proteins spanning the intercellular cleft 
(occludin and claudins), junctional adhesion molecules (JAMs) and cytoplasmic accessory 
proteins (zonula occludens (ZO) -1, -2, -3 and cingulin) bound to the actin cytoskeleton, 
Figure 2. Specifically, claudins form the primary seal of TJ forming dimmers and bind 
homotypically to claudins on adjacent cells, the level of claudin expression determines TJ 
integrity. Occludins are the dynamic regulatory protein responsible on TJ regulation, to 
enhance the transendothelial electrical resitance (TEER) and restrict the paracellular 
permeability. Together, claudins and occludins form the extracellular component of TJs and 
are both required for formation of the BBB. And JAMs can regulate the leukocyte migration 
and it is involved in cell-to-cell adhesion [21]. Basically, ZO proteins serve as recognition 
proteins for TJ placement and as support structure for signal transduction proteins [17]. In 
case of adherens juntions, they are located near the basolateral side of ECs. Cadherin 
proteins span the intercellular cleft and are linked into the cell cytoplasm. The principal 
function of these junctions is holding the cells together giving the tissue structural support 
[13]. TJ and AJ components are known to interact and influence TJ assembly [19].  
 
 
 
Figure 1.2 Simplified explanation of the molecular composition of endothelial TJ at the BBB are shown 
[17]. Three integral proteins form the TJ structure: claudins, occludins and JAM. Claudins produce the 
primary seal of TJ. Occludin function as a dynamic regulatory protein and JAMs are important to 
regulate leukocyte migration. TJ consists of accessory proteins such as ZO. All this mechanisms are 
important to improve the BBB tightness and to reduce the compounds that can cross the BBB.    
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2. Transports across the BBB 
With regard to BBB, it can be said that it is a sort of sanctuary site as it strictly controls the 
exchanges between the blood and brain compartments [8].  As far as small molecule drugs 
are concerned, more than 98% cannot enter the brain [23]. Consequently, crossing the BBB is 
a great challenge.  
Nonetheless several transporters have been established by means of which solute molecules 
move across BBB. The various systems that mediate the transport across BBB can be divided 
into three categories - small molecule, large molecule and efflux transporters (figure 1.3 and 
1.4). Within the small molecule transporters there are two possibilities, the diffusion 
transport and the carrier-mediated transport (CMT). In the first, the passage of molecules 
across the EC of the BBB can occur between adjacent cells (the paracellular pathway) or 
through the cells (the transcellular pathway) [7]. Active efflux transporter (AET) is another 
type of route. Among them the most extensively characterized is adenosine triphosphate-
binding cassete (ABC) transporter family. Macromolecule transporters include receptor-
mediated transcytosis (RMT), absorptive-mediated transcytosis (AMT) and cell-mediated-
transcytosis. This last one refers only to immune cells transport [12]. 
 
Figure 1.3 Different type of blood brain barrier (BBB) transporters adapted from [8]. The scheme is 
divided into three large groups. The first group is about small molecule transporters. The second group 
is about macromolecule transporters. And the last group is about active efflux transporters (AET). Each 
group is divided in various small groups which have different biologic and physical characteristics – 
diffusion and carrier-mediated transport (CMT); receptor-mediated transcytosis (RMT); adsorptive-
mediated transcytosis (AMT) and cell-mediated transytosis (CMT); adenosine triphosphate-binding 
cassete (ABC) transporters. 
 
2.1. Small molecule transporters 
Within the small molecule transporters there are two possibilities, the diffusion transport – 
either simply diffusion or facilitated transport across aqueous channels – and the active 
transport which is mediated by a carrier such as proteins. In the first, the passage of 
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molecules across the ECs of the BBB can occur between adjacent cells (the paracellular 
pathway) or through the cells (the transcellular pathway) [8].  
With regard to transcellular transport, Lipinski and co-researchers developed five rules that 
determine if a compound is more likely to be membrane permeable and easily absorbed by 
the body [24]. In order to achieve his goal, Lipinski analyzed the physicochemical properties 
of more than 2000 drugs and candidate drugs in clinical trials. His work resulted in the 
establishment of five criteria that must be fulfilled by the compounds. These are: no more 
than five hydrogen bond donors (nitrogen or oxygen atoms with one or more hydrogen 
atoms); no more than ten hydrogen bond acceptors (nitrogen or oxygen atoms); a molecular 
mass lower than 500 Da; an compound's lipophilicity, expressed as a quantity known as logP 
(the logarithm of the partition coefficient between water and 1-octanol) lower than 5, and 
compound classes that are substrates of biological transporters are exceptions to the rule 
[24]. It is important to state that the rule of five applies only to absorption by passive 
diffusion of compounds through cell membranes; compounds that are actively transported 
through cell membranes by transporter proteins are exceptions to the rule. Therefore, it is of 
limited significance nowadays [23]. However, it is clear that if the molecular weight of a drug 
molecule is higher than 400 Da or the drug forms more than eight hydrogen bonds, the 
probability of crossing the blood-brain barrier via passive diffusion in pharmacologically 
significant amounts is very low [12].  
Even though the paracellular transport of hydrophilic substances is virtually absent due to the 
unique properties of the TJs, small lipid soluble substances, like alcohol and steroid 
hormones, penetrate transcellularly by dissolving in their lipid plasma membrane [13]. In 
brief, the paracellular transport is a passive movement of a molecule through the aqueous 
route of the intercellular cleft between EC via small pores or flaws in the tight junctions. It 
represents a central functional component of BBB regulation [7]. 
The relationship between the paracellular and transcellular permeability is the key feature in 
the regulation of overall trans-endothelial permeability in the endothelium [25]. 
Concerning to CMT, the active transport is an important transporter that carriers essential 
polar nutrients to cross the brain namely as glucose, amino acids, and purine bases. This type 
of route uses carriers, that is to say, membrane-restricted systems commonly involved in the 
transport of small molecules with a specific size and a molecular weight smaller than 600 Da 
[8]. The solute carriers may be bi-directional, in which case the direction of net transport is 
determined by the substrate concentration gradient; unidirectional either into or out of the 
cell; or involve an exchange of one substrate for another; or be driven by an ion gradient 
depending on electrochemical gradients. It is also a fact that CMT is substrate selective, 
considering that the transport rate depends on the degree occupation of the carrier. 
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Considering that glucose is the main energy source of the brain, glucose transporter-1 plays a 
vital role within the transporters. Since the density of glucose transporter-1 at the abluminal 
membrane is higher than at the luminal, there is a homeostatic control for glucose influx into 
the brain [13, 25]. 
2.2. Macromolecules transporters 
Transcytosis of macromolecules across the BBB via endocytotic mechanisms provides the main 
route by which large molecular weight solutes such as proteins and peptides can enter the 
CNS intact. Macromolecule transporters include RMT, AMT and CMT.   
Extensive studies of RMT have revealed that it offers selective uptake of  many different 
types of ligands, namely plasma proteins, enzymes and growth factors [8], RMT occurs in 
three steps, first the endocytosis of macromolecules specially bound to a receptor on the 
endothelial surface of BBB, followed by diffusion across the endothelium, and exocytosis on 
the opposite site. ECs comprise different receptors, such as transferrin receptor [26], insulin 
receptor [27], lipoprotein receptors [28], and insulin-like growth factors [27].  Regarding 
insulin molecules, the ligand first binds to the receptor present at specialized areas of plasma 
membranes called coated pits. Once bound to ligand, these coated pits invaginate into the 
cytoplasm and form coated vesicles. The ligand is dissociated from receptor by acidification 
of endosome and crosses to the other side of the membrane [23]. 
AMT, also known as pinocytosis, is mediated by electrostatic interaction between positively 
charged substrates and the negatively charged plasma membrane (i.e. heparin sulphate 
proteoglycans) [12]. It is important to state that this process does not involve specific plasma 
membrane receptors. Normally, endocytosis occurs upon binding of the cationic compound to 
the plasma membrane. In order to protect the brain from nonspecific exposure to 
polycationic compounds, this vesicular transport is actively downregulated in the BBB [23].  
Recently, a new transporter was identified which is based on transport of immune cells (like 
monocytes or macrophages) to cross the intact BBB [23]. CMT can transport any type of 
molecules or materials and particulate carrier systems, whereas other mechanisms normally 
permit only solute molecules with specific properties.  
2.3. Active efflux transporters 
As opposed to the above described influx routes, the efflux transporters play a different role. 
It is a fact that they can be considered a "first line of defense", since it is up to them to 
remove xenobiotic molecules and brain potentially neurotoxic endogenous from the brain 
tissue back into the circulation. In addition, they can significantly restrict the entry of 
substrate into brain parenchyma. Up until now, the most extensively characterized efflux 
transporter proteins at BBB is the ABC transporter family [29, 30]. In humans they are a 
 8 
 
 
 
superfamily of proteins containing 48 members which are grouped into 7 sub-families, ABC A 
to G. Among the large number of ABC transporters, only three of them are expressed at the 
blood-brain barrier. The ABCB sub-family contains the multidrug resistance proteins (MDR) of 
which P-glycoprotein (P-gp) is the best-known representative, the ABCC subfamily contains 
the multidrug resistance-associated proteins (MRP) and ABCG sub-family contains breast 
cancer resistance protein (BCRP) [31].  
Regarding to the P-gp, it is a membrane-bound protein (170 kDa) which is present at high 
concentrations in the luminal membrane of the blood-brain barrier endothelium. P-gp has a 
high affinity for a wide range of cationic and lipophilic compounds and therefore limits the 
transport of many drugs, including cytotoxic anticancer drugs, antibiotics, hormones, and HIV 
protease inhibitors. At present, P-glycoprotein is considered the most prominent element of 
selective barrier function that limits xenobiotics from entering the brain [31].  
MRP transports mainly organic anions, glutathione, glucuronide- or sulfateconjugated 
compounds, as well as various nucleoside analogs. Thus it acts as an organic anion transporter 
while it also transports neutral organic drugs. MRP transporters have five isoforms present in 
BBB and BCSFB. 
Another BBB efflux transporter is BCRP, which appears to be expressed in the luminal 
membrane of the cerebral EC in a similar manner to p-glycoprotein. Recent studies suggest 
some cooperation between BCRP and p-glycoprotein inasmuch as they limit xenobiotics from 
entering the brain and compensate one another [23]. Four vital reasons justify the need to 
understand the regulation of these transporters. First of all, it is not known how barrier 
properties can be altered through environmental factors. Second, inflammatory and oxidative 
stress seems to affect ABC transporter expression in other barrier and excretory tissues. 
Third, it is crucial to find out how specific CNS diseases alter transporter function. Finally, it 
is necessary to discover how ABC transporter-specific inhibitors can improve drug delivery 
[31]. 
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Figure 1.4 Mechanisms of transport across BBB [22]. This figure explains the involved mechanism of 
each BBB transporter. 
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3. Drug targeting to the brain 
As said before, the most limiting factor in the development of new strategies of diagnosis and 
therapeutics is the crossing of the BBB. To overcome these limitation, innumerous strategies 
has been studied to improve the pharmacological quantity that it is able to improve 
therapeutic efficiency.  
Firstly, it will be discuss various routes including direct delivery to CNS and direct systemic 
delivery. Then, it will be focus in noninvasive approach, namely it will be discussed 
physiological strategies such as transporter mediated delivery; chemical ones using as 
example cationic proteins; conjugation of drugs with antibodies is a biological strategy and 
the various colloidal carrier systems. Figure 1.5 shows a systematic classification of various 
approaches. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Overview of different strategies for brain targeting of drugs adapted from[23]. Various 
strategies can be used to improve diagnostic and therapeutic – such as invasive ones (systemic and local 
drug delivery), and drug delivery strategies which are modified according to the purpose. 
 
3.1. Novel drug delivery systems 
In this field nanotechnology has been a key feature since it improves the characteristics of 
different agents [32]. Nanotechnology is the creation and use of functional materials with at 
least one characteristic dimension measured in nanometers (scale =10-9). In this technology 
unique phenomena enable novel applications because nanosystems have new properties such 
as large surface-volume ratio, surface charge, small and controlled size. The small size of the 
nanoparticles enables them to penetrate the BBB and facilitates drug delivery across the 
barrier [33]. They have large surface-volume ratio resulting in an increase of local interaction 
 11 
 
 
and thereby increasing the rate of dissolution. At the same time, it is possible to do surface 
functionalization (to improve shelf-life) and to use them as drug carriers (to increase drug 
bioavailability). They allow for controlled and slow drug release in the brain, while 
decreasing peripheral toxicity and side effects [23]. 
Several colloidal system have been studied to improve the BBB crossing such as 
immunolipossomes [34], Solid Lipid Nanopaticles (SLN) [35], poly(butyl cyanoacrylate) (PBCA) 
nanoparticles, chitosan nanoparticles, albumin nanoparticles [36].  
Functionalization of nanocarriers is one of the most important steps or challenges in 
formulating nanocarriers for drug delivery. There are two forms the passive or/and active 
targeting. The passive targeting depending of tissue characteristics like the enhanced 
permeability and retention on many types of tumors [36]. However, in case of human brain 
diseases has not been shown to be effective. The advantage of active targeting is the 
increase of the amount of drug in the target tissue, thereby increasing the pharmacological 
response and reducing systemic side effects [8]. For example, in the case to increase time of 
nanoparticles in the organism and drug bioavailability is necessary use active targeting by 
coating the surface with polyethylene glycol or surfactants like polysorbate 80. Because, if 
the nanoparticles are unmodified, they rapidly are adsorb, mainly by opsonins, and eliminate 
for the organism by the macrophages of the reticuloendothelial system [36]. 
The blood-to-brain transport system is of considerable interest in drug delivery for targeting 
of drug molecules into brain whereas peptides and small molecules may use specific 
transporters expressed on EC [8]. Active physiological or disease-induced drug targeting 
strategies use modified drugs to take advantage of native BBB nutrient transport systems or 
by conjugation to ligands that recognize receptors expressed at the BBB [37]. So, only drugs 
that closely mimic the endogenous carrier substrates will be transported into the brain. 
Nowadays, the research of nanoparticles to target BBB is in RMT, AMT and P-gp mechanisms, 
mainly [37]. 
Accordingly to AMT, the most limitation of this approach is lack of tissue selectivity, which 
can potentially cause side effects [38]. Its approach is based on SynB vectors, penetratin and 
Tat which are various examples of cell penetrating peptides [12]. Cell penetrating peptides 
have an enormous potential for diagnostic and therapeutic applications because their low 
cytotoxicity and the tremendous variety of cargo that can be loaded [8]. Recently, Liu and 
co-workers made a polymer core-shell NPs and on its surface is an anchored Tat molecule. 
The results shown that the surface with TAT improved their uptake cellular by EC [39]. 
RMT has been successful in transporting large drug molecules, drug carrying lipossomes, 
nanoparticles and polymeric complexes even without it [37]. As referred before, RMT has 
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different types of receptors and each receptor has its specific ligands and approaches [8]. In 
the case of diptheria receptor, it is strongly up-regulated in inflammatory conditions, which 
occur in CNS diseases. Recently, Boer and his group worked in CRM197 which is a non-toxic 
mutant of diphtheria toxin and applied it as a targeting vector for drug delivery to the brain 
in diagnostic and therapeutic applications [8]. 
At present, P-gp is considered the most prominent element of selective because it limits 
xenobiotics from entering and accumulates in the brain. So, one of the strategy is inhibits 
efflux transport systems by coating the nanoparticle surface with polaxamer 188 and 
polysorbate 80, for example. Polysorbate 80 is an important component because it is cleared 
adsorb apolyprotein E or B and followed by endocytosis and trancytosis. 
3.2. Administration strategies 
Regarding to direct delivery to CNS, there are different approaches. Accordingly to 
intracerebral (intraparenchymal) delivery, drugs are delivered directly into the parenchymal 
space of the brain. They can be injected by intrathecal catheters, by controlled release 
matrices and by microencapsulated chemicals or recombinant cells [3]. Unfortunately, access 
to the parenchyma is minimal so that a larger dose is required [8]. Alternatively, convection 
enhanced diffusion is used to increase drug uptake by bulk flow. Furthermore, brain implants 
(biodegradable/non-biodegradable polymeric materials encapsulating drugs) can be used for 
the local delivery, too [37]. Another possible route is the intraventricular route, which it is 
also used for drugs (small or large molecules) that do not cross the BBB and where no BBB 
drug delivery is available [40]. Lastly, the intrathecal route involves delivery of drugs into the 
cistern magna of the brain. In this delivery there is a chance of drugs spreading along the 
distal space of spinal canal. For this reason it is best used to treat spinal diseases [3]. 
Another possible to administer drug-loaded is the direct systemic delivery. In intravenous 
delivery, the most commonly used route to administrate larger doses of drugs into the body 
[41], the drug is deliver directly into the general circulation by avoiding its first-pass 
metabolism and has great potential to deliver drugs to almost all neurons in the brain. 
Unfortunately, drug availability is affected by its exposure to peripheral organs and rapid 
clearance. Consequently, there is only a little accumulation of the drug in the brain. 
Similarly, intra-arterial administration allows drugs to access the brain vasculature, before 
they enter peripheral tissue and it is possible to avoid first pass metabolism. By using BBB 
disrupting agents it is possible to increase the effects of this route [3]. The intranasal route is 
based on the principle that drugs exit the submucosa space of the nose into the brain CSF 
compartment. The nasal epithelium has many advantages such as high permeability, 
avoidance of first-pass metabolism, small doses and self-administration. However, this 
administration damages the nasal mucosa and decreases the quantity of drug available [23]. 
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3.3. Chemical Stimuli 
Parallel to last strategies, there has been a significant effort in delivering drugs to the brain 
with BBB disruption [63]. In this approach the substances are directly delivered to the CNS by 
using certain chemical substance or by applying energy (ultrasonic waves or electromagnetic 
radiations). However, the BBB disruption exposes the brain to infection and damage from 
toxins [6]. 
4. BBB models 
It is, indisputable that in vivo models are the best candidates to study the permeability 
phenomena at BBB. However, these resources, typically rats or mice, are scarce, expensive, 
and difficult to study both in detail and real-time. Conversely, ex vivo and in vitro models are 
good alternatives due to their simplicity and controlled environment [11]. Nevertheless, the 
research community also recognizes that reproducing the physiology and the functional 
response of the BBB in vitro is a challenging task. In vitro BBB models started to emerge in 
early 1990s and offer a number of desirable advantages such as cost effectiveness, versatility 
enable controlled, repeatable and non-invasive tests like permeability assays, resistance 
measurements and microscopy. Moreover, they can alter multiple BBB determining factors 
namely: use different cell isolation procedures, cell culture conditions, configuration of cells 
on culture and the cell types (origin and species) [9, 17]; use different systems, such as static 
or dynamic. Nonetheless, in vivo validation is still required [9]. In the follow paragraphs, it 
will be discuss different factors and/or variables that can improve the BBB model and the 
different approaches that have been used to reproduce in vivo BBB.  
4.1. Criteria for in vitro models of the BBB 
At present no in vitro model can faithfully reproduce all the properties and characteristics of 
the in vivo BBB model since the latter has several types of cells and junctions that give rise to 
unique properties [7]. Considering that a single different factor is enough to change the BBB 
fundamental properties, there are several requirements that an ideal in vitro BBB model 
should meet. These include: 
 The ability to enable the expression of TJ between adjacent EC which directly 
facilitate the formation of a selective barrier [9, 42]; 
 In vivo-like asymmetric distribution of relevant transporters which confers 
polarization of the EC [9]; 
 Mechanotransductive effects of shear stress from fluid flow on EC which determines 
cell differentiation and tight junction formation [42]; 
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 The ability to discriminate the permeability of substances according to their 
molecular weight [9, 42]; 
 Maintenance of high electrical resistance that represents the maturity and soundness 
of the structures [43]; 
 The ability to reproduce the effects of a large variety of hemodynamic and 
systematic/inflammatory insults on the BBB [9]; 
 Availability, convenience, predictability and reproducibility [17]. 
An ideal BBB model should be able to reproduce all these characteristics. Unfortunately, the 
techniques available at present do not allow the monitoring of all these features. Therefore, 
new artificial systems such as bioreactors will have to incorporate a number of controlled 
parameters namely control/adjust oxygen and carbon dioxide levels in the culture medium, 
real-time monitoring of BBB integrity, medium sampling, among others. They will also have to 
include an array of computer-controlled sensors to monitor a variety of physiological 
parameters (e.g. glucose, lactate). Advances in this field will only be made possible with the 
introduction of new cell culture apparatus [9]. 
4.2. Overview of current in vitro BBB models 
In the last decades we have witnessed the development of cell culture techniques in which 
cells are immersed in a homogeneous culture medium [44]. The main advantage of cell 
culture is that it allows us to select the stimuli that cells are exposed to, something that 
would be very difficult to reproduce in vivo. Besides, using different types of BBB cells, it will 
be possible use various apparatus which are possible to distinguish into two main groups: 
static and dynamic systems. The main difference is that dynamic models include fluid flow. 
However, most often the final choice of the BBB model is determined by the researcher's 
needs as well as the characteristics of the laboratory, namely time, cost and to what extent 
the model has to be able to reproduce in vivo conditions. Accordingly, either one or the other 
model can be more advantageous depending on the purpose of the investigation [43]. In the 
following sections current in vitro models of the BBB are analyzed; for improve understand of 
each model it will be referred to the corresponding key publications.  
4.2.1. Cell types  
Nowadays, most of the current successful BBB in vitro models are based on primary cell 
cultures [4] due to their high TEER values and low passage brain EC retain which closely 
resemble in vivo models, although the several passages of initial cultures entail the down-
regulation or even the loss of many features [17]. Moreover, there may be a limitation in the 
availability of the primary cells as a result of the accessibility of the animals, while these 
cells are also more susceptible to internal and external contaminations than cell lines. In 
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addition, this approach has high costs and requires time-consuming and special skills for the 
isolation of brain EC. Primary cultures can use mammals such as rats, mice, pigs and bovines. 
Rodent models are advantageous in that they are available and it is possible to use them as 
transgenic animals [17]. However, their small size and the relatively low amounts of EC that 
can be obtained from them leads to the use of other models, namely pigs or bovines [45]. Not 
only it is possible to obtain large quantities of EC (up to 200 million as opposed to 1-2 million 
cells per rat brain) [7], but they also offer good permeability properties, more closely to the 
human BBB. On the other hand, their availability is restricted and they are not so well 
characterized regarding their biochemical or molecular composition [5]. Finally, the use of 
human primary cells is equally restricted by the unavailability of experimental material. The 
source material is usually acquired either from autopsies or biopsies, so this tissue often 
cannot be considered as a healthy resource [4]. Therefore, it was necessary to develop 
immortalized several cell lines [46].  
Immortalized cell lines offer a considerable number of advantages. They are reliable (using 
trusted well-established sources), consistent (cell source is controlled and consistent), long-
lasting (important cell features do not disappear over time), accessible (cells are available to 
be purchased at any time) and preparation time and cost are reduced [44]. Despite lacking 
certain BBB features and having low TEER, there is no doubt that immortalized cell lines are 
an emergent solution for BBB models. Immortalized cell lines are available from many 
species, although the most frequently used models derive from rats [47]. Other models of cell 
lines are the porcine and bovine ones. Though they are available, unfortunately they are far 
less well characterized. They have been used to study changes in protein expression following 
induction by astrocytes and neuroinflammatory responses [4]. Human cells became available 
in the early 1980s and contain excellent characteristics for the study of the developmental 
and pathophysiological processes of the BBB. The best characterized human cell line is the 
hCMEC/D3 which has been shown to retain important BBB characteristics. The hCMEC/D3 
cells show a stable phenotype, the expression of endothelial cell markers, chemokine 
receptors and ABC-transporters. Furthermore, the paracellular permeability is much lower 
compared to other cell lines [48]. Human specimens are undoubtedly the best model, since 
they are the only ones that faithfully reproduce the BBB characteristics [4]. 
As previously mentioned, EC are the principal components of the BBB. However, in the course 
of time it was discovered that other cell types also play an important role both in the 
function and regulation of BBB characteristics. As a result, in vitro models became more 
complex as they began to include glial cells, pericytes, even neurons and microglia in 
different BBB models [7]. 
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Co-culture of EC with glial cells increases TEER by 71 %. It is clear that these cells work in 
synergy to faithfully reproduce the BBB characteristics [44]. There is a formation of more 
stringent inter-endothelial TJ, which in turn constitute a more reliable reproduction of in 
vivo BBB [49].  
With pericytes, it has been established that there is an intrinsic relation between pericytes 
and the formation and maintenance of the cerebral microvasculature structure and functions. 
However, it is still unknown which type of pericytes plays the decisive role in this process 
[43]. More recently, it has been proved that neurons induce BBB related enzymes in cultured 
EC. And the co-culture of these cells has shown that a direct contact among EC and neurons is 
not necessary for the induction of occludin expression [4]. 
4.2.2. Apparatus  
The system semi-permeable plate filters, a vertical side-by-side diffusion support, is the most 
commonly used apparatus for EC culturing. This bidimensional model is a microporous semi-
permeable membrane that separates the luminal (vascular) and the abluminal (parenchymal 
side) compartments and which is submerged in feeding medium [11]. This apparatus is ideal 
to study permeability of drugs across BBB. There are two other main features that make this 
apparatus so attractive: it is easy to establish cultures and its cost is relatively low [15]. On 
the other hand, the semi-permeable membranes cannot reproduce the physiological shear 
stress.  In addition, the lack of antimitotic influences by laminin and flow will increase cell 
cycle rate, which will cause an uncontrolled growth of the EC in a multilayer manner. When 
the tightness of the semi-permeable barrier is measured by TEER and permeability it is 
usually much lower than the in vivo BBB [9]. The source of the cells and the methodology 
employed determine the kind of studies that may be performed: drug transposition through 
BBB, regulation of BBB permeability and influence of pathologies on BBB permeability [43]. 
Culturing cells using tri-dimensional extracellular matrix supports is another recently 
apparatus [50]. Among its main advantages we can list the capacity to enable close 
interactions between cells as well as the formation of quasi-physiological biochemical 
gradient exposure. Furthermore it is good to study specific roles of various extracellular 
proteins in cell differentiation. Despite these advantages, it is more expensive and less 
convenient than static models while, at the same time, it is a complex challenge to address. 
Nowadays, this type of model is applied to drug discovery and transport studies related to a 
variety of organs and tissues [51].  
As opposed to static models, dynamic ones use physical stimuli to create shear stress and, as 
a result, they are able to replicate the physiological environment of in vivo BBB [9]. Bussolari 
and co-researchers made the first attempt to enable the endothelial exposure to flow in vitro 
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by using a purpose-built cone and plate viscometer  [52]. This apparatus allowed them to 
expose cells to a quasi/uniform laminar or pulsatile shear stress. In this case, the level of 
shear stress was determined by the cone angle and the angular velocity. However, since the 
flow represented was turbulent it did not faithfully reproduce the flow experienced in vivo. 
This aspect constitutes a serious disadvantage because it is not possible to obtain reliable and 
significant results. Nonetheless, this apparatus was very important as it was the first step to 
produce dynamic models of the BBB [23]. 
Realizing the importance of shear stress as a vital component of any in vitro model, 
researchers decided to focus on the development of new generations of dynamic in vitro 
systems of which a detailed explanation will follow. The main features of the dynamic In 
vitro Blood-Brain Barrier (DIV-BBB) are the possibility to use co-cultures and the presence of 
intraluminal flow through artificial capillary-like structural supports (hollow fibers) [15]. As a 
result, it is possible to faithfully reproduce the BBB in situ as the EC are cultured in the 
lumen of hollow-fibers inside a sealed chamber and are exposed to flow while the astrocytes 
are seeded in the extraluminal compartment to promote cellular stimuli. This system 
presents low permeability to intraluminal potassium and polar molecules, high TEER, 
negligible extravasation of proteins, the expression of specialized transporters, ion channels, 
and efflux systems. However, this system is not intended to be used in drug permeability 
studies and requires more time and technical skills to be established. Though it is possible to 
characterize cells, this can only be done in a limited way. Finally, to start the process a high 
cell load is required [9]. 
Recently the development of microtechnologies has enabled the creation of a new in vitro 
model of the BBB called MicroBBB. MicroBBB is a poly(dimethylsiloxane) multi-layered device 
with a membrane in between which separates the top and bottom channel. Although this 
apparatus is an entirely new creation, it also enables cell culturing procedure, permeability 
tests and TEER measurements [53]. When compared to the models previously discussed, 
MicroBBB presents more advantages including rapid and low-cost fabrication, controlled and 
repeated environment with realistic microcirculatory dimensions and environment, 
physiological fluid flow and shear stress and much thinner culture membrane which decreases 
the distance between co-cultured cells. However, the top-bottom architecture of this model 
limits simultaneous real-time visualization of both the vascular and neuronal sides of the BBB 
[4]. Another key feature of this model is that it can be used to monitor drug permeability, as 
well as changes in barrier function, which occur in response to various environmental stimuli 
namely diseases. 
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4.2.3. In silico models 
The incredible development of computer technology and sophisticated algorithms allowed the 
creation of new methods based on computer simulation called in silico models [7]. In silico 
models offer various advantages, the most important of which lies in accurate predictions. 
Not only is there no need to recur to laboratory experiments, but the process is also cheaper 
and requires fewer time-consuming laboratory experiments [23]. The potential to accelerate 
drug discovery is the outstanding quality of in silico models for medicine. This technology 
allows the compounds to be synthesized, pre-screened, and virtually tested, so that it is 
possible to predict how they will cross the BBB. Therefore, it will be possible to study the 
efficacy and the bio-availability of novel drugs in terms of brain permeability, transport 
properties and toxicity [9]. On the other hand, the complex nature of BBB is not taken into 
full consideration, which leads to uncertain results. Though in silico models represent future 
breakthroughs in the pharmaceutical drug development, clinical studies will still have to be 
supported by in vitro and in vivo models in order to collect a number of crucial 
physicochemical measurements [7, 9] .  
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Chapter 2  
Aim 
The main goal of the present thesis was a further characterization and improvement of an in 
vitro BBB model, using three different type of human cells, as a tool to study biological and 
functional BBB alterations and as a key to assess permeability of anti-cancer drugs.  
General goals  
1. Develop an in vitro BBB model that will mimic more properties and characteristics of 
the in vivo BBB; 
2. Integrity evaluation based on the alterations applied through the in vitro model; 
3. Development of Camptothecin-loaded SLN (CPT-SLN) for brain delivery; 
The thesis work was divided into two phases. First, it was analyzed the state of the art, 
definition of the work plan and requisition of the laboratory material. This part was done 
during September and October and also a few months before, during the 2nd semester. On the 
second phase was developed the laboratory work at Laboratory of Pharmaceutical 
Tecnnologic, Department of Drug Sciences, Pharmacy Faculty, University of Porto, the 
majority of the work, and at INEB, University of Porto. This part was realized from October 
until June. 
To develop and evaluate the integrity of triple co-cultured model, it was seeded hCMEC/D3 
cell line, primary human astrocytes and U87 cell line. During the time on culture, TEER 
measurements were taken. Moreover, on the last day on culture were performed different 
experiments such as permeability assay, immunocytochemistry, optical microscopy, 
electronic microscopy and flow cytometry to analyze the cell morphology, expression of 
cellular specific markers and barrier integrity.  
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Then, to develop CPT-SLN for brain delivery it was selected the drug-SLN formulation. And it 
was produced and characterized CPT-SLN by mean size, size polidispersity, surface charge 
and association efficiency. Finally, it was done viability assays using different CPT 
formulations.  
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Chapter 3  
Materials & Methods 
Materials 
Dulbecco’s Modified Eagle’s Medium (DMEM), Fetal Bovine Serum (FBS), glutamine, penicillin-
streptomycin, chemically defined lipid concentrate, HEPES and trypsin-
EthyleneDiamineTetraacetic Acid (EDTA), Occludin-mouse monoclonal antibody-Alexa Fluor 
594, Claudin-5-mouse monoclonal antibody-Alexa Fluor 488, N2 suplemment, Wheat Germ 
Agglutinin (WGA) – Alexa Fluor 488 and GeltrexTM LDEV-Free Reduced Growth Factor 
Basement Membrane Matrix were provided by Gibco (Invitrogen Corporation, Spain). 
Hidrocortisona - γ-irradiated, Dulbecco’s Phosphate Buffered Saline (DPBS) Modified, without 
calcium chloride and magnesium chloride, fluoroshield™ with 4',6-diamidino-2-phenylindole, 
dihydrochloride (DAPI) mounting medium, paraformaldehyde, giemsa stain, rat tail collagen 
type I, human basic fibroblast growth factor (bFGF), ascorbic acid, lithium chloride solution, 
Fluorescein isothiocyanate – Dextran (FD) average molecular weight of 4.000, 40.000 and 
70,000 Da, triton-X 100, Bovine Serum Albumin (BSA) were provided by Sigma-Aldrich 
(Portugal). EBM-2 medium were provided by Lonza. The 12-well semi-permeable plate filters, 
PE-mouse anti-human GFAP were sold by BD, Biosciences, USA. VE-Cadherin-FITC were 
obtained from Miltenyi Biotec (USA). AlamarBlue™ cell viability reagent assay were obtained 
by Thermo Scientific (USA). 
Cetyl palmitate was a gift from Gattefossé SA, (St Priest, France). The surfactant polysorbate 
80, organic solvents (acetonitrile, triethylamine) for high performance liquid chromatography 
(HPLC) and Dimethyl sulfoxide (DMSO) were supplied by Merck KgaA, (Darmstadt, Germany). 
Purified water was of MilliQ ® -quality. 
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Methods 
3.1. Cell Culture 
3.1.1 - Cells description 
Immortalized mouse EC (b.End3) cell line is sold by American Type Culture Collection. bEnd3 
is an immortalized mouse EC. The cells were transformed by infection with the NTKmT 
retrovirus vector that expresses polyomavirus middle T antigen. The endothelial nature of 
these cells was confirmed by the observed expression of von Willebrand factor and uptake of 
fluorescently labeled low density lipoprotein (LDL).  
Immortalized human brain capillary EC (hCMEC/D3 cell line) was a kindly donated by Dr. PO 
Couraud (INSERM, France). The original brain EC used for the generation of the cell line were 
isolated from human brain tissue following surgical excision of an area from the temporal 
lobe of an adult female with epilepsy. The hCMEC/D3 cell line had been immortalized by 
lentiviral transduction of the catalytic subunit of human telomerase and SV40-T antigen into 
very early cultures of adult human brain endothelial microvascular cells [54]. hCMEC/D3 
between passage 25 and 33 were used in all studies. 
The human astrocytoma U87 cell line is a commercial cell line sold by American Type Culture 
Collection. It derived from a human glioblastoma (astrocytoma), classified as grade IV as of 
2007 with adherent properties.  
Primary astrocytes are human brain progenitor-derived astrocytes with adherent properties 
sold by Gibco. It is the only that are primary cells, so the number of cells is more limited than 
the other ones to perform the in vitro models experiences. 
3.1.1.1  Cell line conditions 
For culturing, hCMEC/D3 were seeded in a concentration of 25 000 cells/cm2 and grown in 
EBM-2 medium (Lonza, Basel, Switzerland) supplemented with 10 mM HEPES, 1 ng/mL human 
Basic Fibrolast Growth Factor (bFGF), 1.4 µM hydrocortisone, 5 µg/mL ascorbic acid, 
penicillin–streptomycin, chemically defined lipid concentrate and FBS. All culture ware and 
semi permeable filters were coated with 150 µg/mL rat tail collagen type I for 1 h at 37º C. 
Collagen is a fibrous protein which presents a rope-like triple helix, providing strength to the 
extracellular matrix and this specific type of collagen  is the most common fibrillar collagen 
(90%). Cells were cultured in the incubator at 37º C with 5% CO2, 95% fresh air in a humidified 
incubator (Heraeus Hera Cell incubator). Cell culture medium was changed every 2-3 days.  
The human glioma U87 cell line and b.End3 cell line were maintained in complete Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Gibco, Invitrogen Corporation) supplemented with 10% fetal 
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bovine serum (FBS), 1% glutamine (2mM) and 1% antibiotic-antimycotic (Gibco, Invitrogen 
Corporation: 10,000 units/mL penicillin G sodium, 10,000 mg/mL streptomycin sulphate). 
Cells were subcultured every 3-4 days using trypsin-EDTA. 
Primary astrocytes were maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM, 
Gibco, Invitrogen Corporation) supplemented with 10% fetal bovine serum (FBS), 1% 
glutamine (2mM),  1% antibiotic-antimycotic (Gibco, Invitrogen Corporation: 10,000 units/mL 
penicillin G sodium, 10,000 mg/mL streptomycin sulphate) and 1% N2 supplemment (Gibco, 
Invitrogen Corporation). The medium has been specifically formulated for the growth and 
maintenance of human astrocytes while retaining their phenotype.  All culture ware and semi 
permeable filters were coated with 0.1 mg/mL GeltrexTM LDEV-Free Reduced Growth Factor 
Basement Membrane Matrix (Gibco, Invitrogen Corporation) for 1 h at 37º C. It is used for 
promotion and maintenance of many cell types specifically primary cells. The major 
components of this matrix product include laminin, collagen IV, entactin and heparin sufate 
proteoglycan. Cells were subcultured every two times per week using trypsin-EDTA. 
3.1.2 - Cell line laboratory concepts 
3.1.2.1 - Cell subculture  
Firstly, the cells were examined to inverted microscopy to study any signal of contamination. 
When the cells present 70-80% of confluence, the medium was aspirated and they were 
washed with Dulbecco´s Phosphate Buffered Saline (DPBS) two-three times to remove all 
residues. Then, they were detached using trypsin-EDTA (1x) from the flask, only a few 
minutes because trypsin cuts the adhesion proteins in cell-cell and cell-matrix interactions 
and EDTA is a calcium chelatator, so it is necessary to pay attention of the time in contact 
with the cells. In this way, it was necessary added medium to block the action of this 
enzyme. The cell suspension was put in a tube and centrifuged at 1500 rpm, 21 ºC during 5 
minutes. After the centrifuge, it was removed the supernatant and the pellet was mixed and 
resuspend in medium. To count the cells, it was necessary to pipette 10 µL of cells and 90 µL 
of trypan blue and it was expelled the cell suspension immediately to the edge of the 
Neubauer chamber. Then, under the inverted microscope the viable cells were counted. 
Using the following formula it was possible to know the number of cells in total volume 
(where n=number of cells in Neubauer chamber; d=dilution ratio). 
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3.1.2.2 - Cell freezing  
Instead of using the cells for subculture, it is better freeze them, in order to prevent 
phenotypic degeneration, characteristic of high passage numbers. For that, following the 
method before, after counted the cells the pellet was gently resuspended in Freezing 
medium consisting of complete culture medium with 5-10% (v/v) DMSO (Sigma), a 
cryopreservant, and transferred to adequate cryovials, on concentration of 2-3 millions of 
cells per 2 mL. These cryovials were stored at -80ºC freezer. 
3.1.2.3 - Cell thawing 
To prevent prevent as faster as possible the DMSO of the freezing medium, a cryovial was 
rapidly removed and thawed in a 37ºC water bath. Cells were transferred to complete 
medium and centrifuged at 1500 rpm for 5 minutes. The supernatant were discarded and the 
pellet was gently ressuspended in pre-warmed complete medium and transferred to tissue 
culture flasks.  
3.2 In vitro models 
Firstly, to improve laboratory skills and to learn how to manipulate an in vitro model it was 
performed monocultures using bEnd3 cell line on the semi-permeable filters. Then, 
monocultures of hCMEC/D3, co-cultures of hCMEC/D3 and U87 cell line, co-cultures of  
hCMEC/D3 and primary astrocytes and a triple co-culture of hCMEC/D3, U87 cell line and 
primary astrocytes cells were cultured on semi-permeable plate ﬁlters which was developed 
based on a rather simpliﬁed view of the BBB, Figure 3.1. The semi-permeable filter is 
composed by an insert filter and an acceptor well, with the apical chamber mimicking the 
blood and the basolateral one mimicking the brain side. 
Figure 3.1 Schematic illustration of [A] in vitro BBB model and [B] in vivo BBB. Endothelial cells will 
seeded on the apical chamber (blood) which is in the internal part of the in vitro model. Astrocytes will 
seeded on the inverted side of the insert in basolateral chamber (brain) but in direct contact with 
endothelial cells and the glioma cell line will seeded also on the basolateral chamber (brain), however 
in the bottom of the plate. Adapted from [55].   
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The microporous membrane interface allows nutrient exchange and the passage of cell-
derived and exogenous substances. The speciﬁc model selected for this work was the 12-well 
clear polyester semi-permeable plate ﬁlters, which features a vertical side-by-side diﬀusion 
system with 1.0 µm pore size. It has tissue-cultured treated surface; eﬀective growth area of 
membrane about 0.9 cm2 and membrane diameter about 10.5 mm. The properties of the 
clear membrane allow an easier observation under the microscope. Furthermore, the smaller 
size membranes are primarily used in drug transport studies and it is suitable for the study of 
co-cultures as cell migration.  
The apical part of the insert was filled with 0.5 mL and the basolateral side with 1.5 mL. To 
avoid to the monolayer uneven hydrostatic pressure, it was aspirate medium from the bottom 
first. When adding fresh medium, it was filled the top chamber first. For the same reason, it 
is important to consider the amount of media in each chamber, so the height of the fluid in 
the chamber should be at same level as inside.  
3.2.1 In vitro models development 
3.2.1.1 Endothelial rat cells on monoculture 
 
 
 
 
 
 
Figure 3.2 The experimental procedure for monoculturing the bEnd3 cell line. [A] Endothelial cells 
were seeded onto the luminal side of the semi-permeable ﬁlter during 7 days. 
Endothelial mouse cells were seeded at initial concentration of 1.8x10⁵ cells/cm² and of 
0.9x10⁵cells/cm², Figure 3.2. Cells were cultured during 21 days in the incubator at 37⁰ C 
with 5% CO2, 95% fresh air in a humidified incubator (Heraeus Hera Cell incubator). Cell 
culture medium was changed at 3 days.  
During the time on culture, the resistance of the barrier was analyzed.  
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3.2.1.2 - Endothelial human cells on monoculture 
 
 
 
 
 
 
Figure 3.3 The experimental procedure for monoculturing the endothelial cells. [A] The ﬁlter was 
coated with rat tail collagen type I during 1 hour and [B] Endothelial cells were seeded onto the luminal 
side of the semi-permeable ﬁlter during 7 days.  
Before seed the cells, it was necessary to coat the membrane with rat tail collagen type I 
(Invitrogen, Gibco) at 150 ug/mL during 1 hour, Figure 3.3 – A. Then, it was washed the filter 
with DPBS because of the acetic acid present on this collagen solution. hCMEC/D3 cell line 
was cultured, Figure 3.3 – B, at different concentrations at 5x104 cells/cm2; 4,6x104 
cells/cm2; 2,3x104 cells/cm2 and 1,15x104 cells/cm2 on the apical side of the semi-permeable 
filter. Cells were cultured during 11 days in the incubator at 37⁰ C with 5% CO2, 95% fresh air 
in a humidified incubator (Heraeus Hera Cell incubator). In the follow experiments was used 
the 4,6x104 cells/cm2 initial concentration during seven days on cell culture. Cell culture 
medium was changed at 2nd, 4th and 7th days and it was added lithium chloride with fresh 
medium.  
During the time on culture, the resistance of the barrier was analyzed. Also, to characterize 
the model it was performed permeability assays, flow cytometry analysis, 
immunocytochemistry technique and optical microscopy using giemsa.  
3.2.1.3 –EC and U87 cell line on co-culture 
 
Figure 3.4 The experimental procedure for co-culturing the endothelial cells and U87 cell line. [A] The 
ﬁlter was coated with rat tail collagen type I during 1 hour. Then, [B] Endothelial cells were seeded 
onto the luminal side of the semi-permeable ﬁlter and [C] On 2nd day, U87 cell line was seeded on the 
abluminal side of the model with the same initial concentration of endothelial cells and co-cultured for 
5 days. 
Initial was used the same procedure to culture endothelial human cells, Figure 3.3 - A and B. 
At the end of the second day was added U87 cell line in the same initial concentration of EC, 
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4,6x104 cells/cm2 at the abluminal side, Figure 3.4 - C. Cells were cocultured for an 
additional 5 days in the incubator at 37⁰ C with 5% CO2, 95% fresh air in a humidified 
incubator (Heraeus Hera Cell incubator). Cell culture medium was changed at 2nd, 4th and 7th 
days and it was added lithium chloride with fresh endothelial medium on the luminal side and 
DMEM complete on the abluminal side of the in vitro model.  
During the time on culture, the resistance of the barrier was analyzed. Also, to characterize 
the model it was performed permeability assay, flow cytometry analysis, 
immunocytochemistry and Scanning Electron Microscopy (SEM). 
3.2.1.4 – EC and astrocytes on coculture 
 
Figure 3.5 The experimental procedure for coculturing the endothelial cells and astrocytes on different 
sides of the semi permeable ﬁlter. [A] The ﬁlter was coated with rat tail collagen type I during 1 hour. 
Then, [B] the filter were coated with Geltrex, basement membrane substitute. [C] Astrocytes were ﬁrst 
seeded onto the abluminal side of the inverted semi permeable ﬁlter and allowed to adhere for 3h. [D] 
The ﬁlter was ﬂipped back and endothelial cells were seeded onto the luminal side of semi-permeable 
ﬁlter and cocultured with astrocytes for 7 days. 
Before seed the cells, it was necessary coated the membrane with rat tail collagen type I, 
Figure 3.5 - A. Then, it was added Geltrex (Invitrogen, Gibco) to coat the other side of the 
insert during 1 hour, Figure 3.5 – B. The main goal of this coating is to permit the fast 
differentiation and growth of the primary astrocytes. Then, it was culture astrocytes at ratio 
1 to 23 EC in the opposite side of the insert and are maintained in this position during 3 
hours, when necessary medium was added, Figure 3.5 - C. The ﬁlter was ﬂipped back and it 
was seeded EC on the abluminal side, Figure 3.5 - D. Cells were cocultured during 7 days in 
the incubator at 37⁰ C with 5% CO2, 95% fresh air in a humidified incubator (Heraeus Hera Cell 
incubator). Cell culture medium was changed at 2nd, 4th and 7th days and it was added lithium 
chloride with fresh endothelial medium on the luminal side and DMEM complete with N2 
supplemented on the abluminal side of the in vitro model. 
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During the time on culture, the resistance of the barrier was analyzed. Also, to characterize 
the model it was performed permeability assay and Scanning Electron Microscopy (SEM). 
3.2.1.5 - EC, astrocytes and U87 cell line on cell culture 
 
Figure 3.6 The experimental procedure for co-culturing the endothelial cells, astrocytes and U87 cell 
line on different sides of the semi permeable ﬁlter. [A] The ﬁlter was coated with rat tail collagen type 
I during 1 hour. Then, [B] the filter were coated with Geltrex, basement membrane substitute. [C] 
Astrocytes were ﬁrst seeded onto the abluminal side of the inverted semi permeable ﬁlter and allowed 
to adhere for 3h. [D] The ﬁlter was ﬂipped back and endothelial cells were seeded onto the luminal side 
of semi-permeable ﬁlter and co-cultured with astrocytes for 7 days. [E] On 2nd day, U87 cell line was 
seeded on the abluminal side of the model with the same initial concentration of endothelial cells and 
cultured for an additional 5 days. 
Initial was used the same procedure to co-culture EC and astrocytes, Figure 3.5 - A and D. 
And, at second day was added U87 cell line at same initial proportion of EC, Figure 3.6 - E.  
Cells were co-cultured for an additional 5 days in the incubator at 37⁰ C with 5% CO2, 95% 
fresh air in a humidified incubator (Heraeus Hera Cell incubator). Cell culture medium was 
changed at 2nd, 4th and 7th days and it was added lithium chloride with fresh endothelial 
medium on the luminal side and DMEM complete with N2 supplemented on the abluminal side 
of the in vitro model. 
During the time on culture, the resistance of the barrier was analyzed. Also, to characterize 
the model it was performed permeability assay and Scanning Electron Microscopy (SEM). 
3.2.2 - In vitro models characterization 
3.2.2.1 – TEER 
In order to be sure the amount and formation of endothelial tight junctions, the cell 
monolayer integrity was periodically inspected under a microscope and TEER were performed 
using an EVOM voltohmmeter (World Precision Instruments, Sarasota, FL, USA). Briefly, the 
lengths of the electrodes are unequal allowing the longer electrode (external) to touch the 
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bottom of the basolateral side while preventing the shorter electrode (internal) from 
reaching the bottom of the apical side. An increase of TEER values indicate an increase of the 
confluence of the monolayer and of its integrity. The resistance value (Ω × cm2) of an empty 
filter was subtracted from each measurement. Six measurements were taken per filter, and 
each culture condition was performed with triplicate filters to obtain average TEER and 
standard deviation.  
3.2.2.2 Permeability transport experiment 
The apparent permeability based on the flux of a molecule across the barrier with known 
molecular weight can be also a measure of the integrity of the in vitro BBB model. The fluid 
flux is linearly proportional to the dose applied. So, more abluminal fluorescence units more 
it will be the molecule quantity that had crossed the barrier.  
On 7th day, the integrity of the membrane was accessed by FD4 (average molecular weight 
4.000 Da), FD40 (average molecular weight 40.000 Da) and FD70 (average molecular weight 
70.000 Da) permeabiliites at initial concentration of 1 mg/mL. Each solution of FD was 
dissolved on EBM-2 and it was added 500 µl to the upper chamber of the semipermeable plate 
filters and on the bottom chamber, it was added only DMEM. The plate was homogenized 
during 1 minute, before sampled. The lower chamber was sampled at various time periods 
(30, 60, 90, 120 and 150 minutes), and the amount was determined using a fluorescence 
multiwall plate reader at excitation wavelength to 488 nm and the emission wavelength to 
520nm. 
The apparent permeability (Papp) was calculated using the following equation: 
 
Where Papp is the apparent permeability (cm/s), Q is the amount of molecule transported 
per minute (µg/min), A is the surface area of the filter (cm2), C is the initial concentration of 
the molecule and t is the time (seconds). The data it will be presented graphically as a 
percent change from control values. 
3.2.2.3 Flow cytometer studies 
To confirm the initial seeding proportions and guarantee the glioma cell line and endothelial 
phenotype, flow cytometry experiments were done using specific astrocyte and endothelial 
markers. On preliminary studies, it was tested different incubation times, temperatures and 
antibody ratio. Control negative experiments were done in parallel. 
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Cell suspensions of hCMC/D3 cells were prepared from confluent cell monolayers dispersed 
with trypsin-EDTA. The VE-Cadherin marker plays a fundamental role in maintaining 
endothelial integrity, barrier function, and leukocyte extravasation. Loss of VE-cadherin 
expression from/or disorganized VE-cadherin distribution at cell junctions directly influences 
monolayer integrity and endothelial permeability. After obtained a cellular suspension, cells 
were centrifuged at 300xg for 10 minutes. Upon washing with DPBS containing 0.5 % BSA and 
2mM EDTA buffer, the cell pellet was resuspended in 100 µL DPBS containing 0.5 % BSA and 
2mM EDTA buffer with 10 µL of the VE-Cadherin- FITC antibody and incubated at 4-8 ºC during 
30 min.  
Upon washing and centrifuged, the cell pellet of all samples were resuspended on 100 µl of 
DPBS and were performed flow cytometry analysis using BDFACS Calibur (BD Biosciences, 
USA).  
Briefly, the solution of 0.5 % BSA and 2mM EDTA buffer is used, because EDTA can avoid cell 
clumps during flow cytometer acquisition and BSA compound reduces the chance of 
heterophilic antibody interference and can decrease non-specific binding of the antibodies.  
3.2.2.4 - Immunofluorescence 
Membrane markers  
On the 2nd, 4th, 7th, 9th and 11th days, cells were washed three times with DPBS and fixed in 4% 
paraformaldehyde for 10 min. The cell membranes were labeled with 5.0 μg/mL Alexa Fluor 
488–WGA, incubated for 10 minutes at 37°C. After three washes with DPBS, the cells nuclei 
were labeled 4′, 6-Diamidino-2-pheny-lindoldihydrochloride (DAPI) at a concentration of 300 
nM for 5 min at 37°C. Cells were washed an additional three times in PBS and visualized using 
a Nikon Eclipse E4000 (Nikon Instruments Inc., USA). Photographs were run by NIS Elements 
(Nikon Instruments Inc., USA). 
Endothelial specific markers 
On the 7th day, the cells were washed three times with DPBS and fixed in 4% 
paraformaldehyde for 10 min at room temperature (RT). They were then washed three times 
for 5 minutes with DPBS. Upon washing, cells were permeabilized by incubating for 10 
minutes with 0.1% (v/v) Triton X-100 in DPBS. Following permeabilization, cells were washed 
for 5 minutes with DPBS. In order to prevent non-specific binding, it was added a blocking 
solution DPBS with 0.05% Tween 20 containing 3% (w/v) BSA for 30 minutes. Then the 
antibody was dilute to its optimal working concentration in appropriate dilution DPBS 
containing 0.5 % BSA and 2mM EDTA at ratio 1:100 (Claudin-5-Alexa Fluor 488, Occludin-Alexa 
Fluor 594) and at ration 1:10 VE-Cadherin-FITC. In case of VE-Cadherin marker, it was not 
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submitted to the permeabilization procedure. It was added 250 µL of diluted antibody per 
well and incubated during 30 minutes at 4-8 ºC. After three washes with DPBS, the insert 
membrane was removed and put onto the glass coverslips. Then, the cells nuclei were 
labeled with DAPI using the mounting medium and visualized using a Nikon Eclipse E4000 
(Nikon Instruments Inc., USA). Photographs were run by NIS Elements (Nikon Instruments Inc., 
USA). 
3.2.2.5 - Giemsa staining 
On the 2nd, 4th, 7th, 9th and 11th days, cells were fixed in methanol for 2 min and stayed on air 
dry at room temperature. The cell were labeled with Giemsa stain (1:20) during 30 minutes.  
Cells were washed several times with deionized water and visualized using an inverted 
microscope (Motic Incorporation). Briefly, giemsa stain is used to differentiate nuclear and/or 
cytoplasmic morphology, the nuclei will be varying shades of purple and cytoplasmic staining 
will be varying shades of light pink of the bone marrow cells.  
3.2.2.6 - Scanning Electron Microscopy 
The surface of the EC and the astrocytes cells were observed by SEM on 7th day. Briefly, the 
insert membrane was removed and fixed with 3% glutaraldehyde in 0.1M sodium cacodylate 
solution solution pH 7.4 for 45 min at 4°C. Then, the membrane was washed with cacodylate 
buffer for 5 min. After dehydrated in graded ethanol, on the insert membrane was added 
HDMS solution for 10 minutes and air-dry. Finally, the samples were put on the support and 
coated with Au/Pd for 60 seconds and with a 15mA current. The samples were examined by a 
Quanta 400FEG ESEM / EDAX Genesis X4M. 
3.3 Camptothecin loaded Solid Lipid Nanoparticles 
SLN have a solid incomplete matrix. These nanoparticles have a hydrophobic core, an ideal 
solution to transport hydrophobic drugs, avoiding drug degradation for example. As a result, 
the strategy is incorporate an anti-cancer drug, camptothecin, as target U87 cell line and 
cross the BBB, into SLN. In the sequence of the work done by Martins and co-researchers [35, 
56, 57] in the production and characterization of this new drug model. 
 
3.3.1 – Production of Solid Lipid Nanoparticles 
 
3.3.1.1 - High shear homogenisation followed by ultrasonication 
For smaller particle size combination of both ultrasonication and high shear homogenisation is 
required. The formulations containing the lipid cetyl palmitate and the surfactants 
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polysorbate 80 were prepared at concentrations of 5% (w/w) of lipid, 2% (w/w) of surfactant 
and 0.01 % (w/w) of camptothecin. The lipid and surfactant mixture was melted at 
approximately 5 to 10 ºC above the melting point of the lipid. This mixture is then combined 
with an aqueous solution heated at the same temperature.  A hot pre-emulsion is formed by 
high shear homogenisation using with an ultra-turrax T25 at 8000 rpm during 40 seconds. This 
hot pre-emulsion is converted into a nanoemulsion when processed in an ultrasonic probe at 
80% amplitude for 2.5 min. The particle size is decreased mainly by cavitation. The 
nanoemulsion is cooled down leading to recrystallisation of the lipid and formation of lipid 
nanoparticles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Schematic representation of SLN production by high shear homogenisation 
followed by ultrasonication adapted from [35]. 
3.3.2 – Characterization 
 
3.3.2.1 – Mean particle size and size distribution 
 
To analyse the particle size and distribution of the nanoparticles were used two different 
equipments, Zetasizer Nano ZS laser scattering device and Malvern Mastersizer 3000. 
Firstly, particle size and distribution (polydispersity index) was determined by dynamic light 
scattering (DLS), using a Zetasizer Nano ZS laser scattering device (Malvern Instruments Ltd., 
Malvern, UK) with a range from 0.0003µm to 10µm. Prior to the measurements, all samples 
were diluted (1:10) using purified water to yield a suitable scattering intensity, the average 
count rate indicates that the dilution applied to the formulations was appropriate. The 
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measurements were always performed in triplicate. The available software (Zetasizer Nano 
Series V6.20) was used to correlate the intensity of scattered light with the hydrodynamic 
radius of the spherical particle.  
Briefly, DLS measures the light scattered from a laser that passes through a colloidal solution. 
As a result of the brownian motions, there are changes in scattered light intensity. So, DLS 
does not directly measure the diameter of particles, but rather detects the fluctuations of 
light signals caused by the Brownian motion of the particles to calculate their sizes. More DLS 
technique can give information about polidispersion index that indicates the state of particle 
aggregation of nanoparticles in suspension. 
Laser diffractometry was additionally performed in order to analyse the particle size, using a 
laser diffraction particle size analyser (Malvern Mastersizer 3000, Malvern Instrument, Ltd) 
with a range from 0.01 to 3500 µm. The determination was performed at room temperature 
using 1.1 for the refractive index, 0.01 for the absorption index, laser obscuration around 6% 
and Scattering Model Mie. The dispersant was water with refractive index of 1,330. The 
particle size distributions of the nanoparticles were determined and the results were 
respectively expressed by the mean volume diameter (D [4, 3]), 10% percentile (D [0, 10]), 
median (D [0, 50]) and 90% percentile (D [0, 90]). The LD data were expressed using volume 
distributions, and given as diameter values corresponding to percentiles of 10%, 50%, and 
90%. The span value is a statistical parameter useful to characterize the particle size 
distribution, and was calculated according to: 
 
 
 
3.3.2.2 – Surface charge 
 
The electrophoretic mobility (zeta potential) of the nanoparticles and ultimately their 
surface charge was measured by combining laser Doppler velocimetry and phase analysis light 
scattering (PALS) using a Zetasizer Nano ZS (Malvern, Worcestershire, UK). Surface charged 
particles within the dispersion migrated toward the electrode of opposite charge and the 
velocity of particles migration was converted in zeta potential values by using the 
Smoluchowski’s equation. Zeta potential is a physical property present in any particle in 
dispersion and it is an indirect measurement of the surface charge. The magnitude of the 
zeta potential gives an indication of the potential long-term stability of the colloidal 
dispersions and also predict interactions between the nanoparticles and the cellular 
membranes that can occur due to electrostatic interactions. 
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3.3.2.3 – Association Efficiency 
 
Association Efficiency were determined by two methods, indirect and direct one. In both 
methods camptothecin association efficiency was determined by High Performance Liquid 
Chromatography (HPLC), as previously described [56]. Briefly, the chromatographic analysis 
was performed at 30 °C on an analytical reversed-phase (RP) Mediterranea™ Sea18 column 
(150 mm × 4.0 mm, 5 μm, Teknokroma, Spain) protected with a precolumn Ultraguard™ 
(Guard column Sea18, 10 mm × 3.2 mm, Teknokroma, Spain). The optimised method used a 
binary gradient mobile phase with 1% (v/v) triethylamine buffer at pH 5.5 (pH adjusted with 
acetic acid) as mobile phase A and acetonitrile as mobile phase B. A flow rate of 1.2 mL/min 
was used with a 10 μL injection volume. The program started with a gradient of 75%A and 
25%B and after 1 min the gradient changed continuously until the minute seven were it 
reaches the gradient of 40%A and 60%B which was maintained until minute nine. Afterwards, 
the gradient was changed again to 75%A and 25%B and remained constant until minute 
sixteen. The eluted peaks were monitored at excitation and emission wavelengths of 360 and 
440 nm, respectively. Stock solutions of CPT were prepared daily in DMSO at concentration of 
1 mg/mL and further diluted in 9 mM phosphate buffer pH3 to a concentration of 10 μg/mL. 
Standard solutions were prepared by dilution in 9 mM phosphate buffer pH3 o a final CPT 
concentration between 10 and 100 ng/mL.  
Subsequently, the quantification of the compound was carried out by measuring the peaks 
areas in relation to the standards. 
Indirect Method  
Upon separation of camptothecin-loaded SLN from free camptothecin by ultracentrifugation. 
Prior to first ultracentrifugation (100,000×g, 20 min) SLN dispersions were diluted 10 times in 
PBS buffer 50 mM pH 10.5. The supernatant collected was further diluted 100 times in PBS 
buffer. And, the supernatant resulted from the second ultracentrifugation (100,000×g, 20 
min) was analysed and the camptothecin concentration in SLN was detected indirectly by 
HPLC. 
Using the indirect method, the association efficiency of a drug in SLN, the aqueous phase is 
separated from the lipid particles and subsequently drug content of the aqueous phase is 
determined. The amount of drug measured in the aqueous phase is considered the amount of 
drug not incorporated. The following equation is used to calculate the AE:  
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Direct method 
 
As described by Das and co-researchers [58], the freshly prepared formulation, diluted 1:5, 
was ﬁltered through a 5 µm nitrocellulose membrane ﬁlter (Millipore, Ireland) to remove 
unencapsulated drug crystals. The drugs used in this study have high solubility in methanol, 
whereas the lipids are insoluble in methanol. Hence, 9 mL methanol was added to a 1 mL 
ﬁltered formulation and thoroughly mixed to extract the drug from the lipid matrix. The 
mixture was then centrifuged at 5000 rpm for 15 min and supernatant was ﬁltered through a 
0.45 µm PTFE syringe ﬁlter (Millipore, Ireland). The supernatant was again diluted 1:1000 
with 9 mM phosphate buffer pH3 to the HPLC assay calibration range. The amount of drug in 
the ﬁltered supernatant was measured by HPLC. The amount of drug in the ﬁltered 
formulation was then calculated considering the dilution factor. However, this process also 
measures the unencapsulated drug which is dissolved in the aqueous phase (soluble 
unencapsulated drug), however camptothecin is practically insoluble in water (2.5 µg/mL) [59], 
as result the association efﬁciency was calculated using as below: 
 
3.4. In vitro studies   
3.4.1 Viability studies 
 
The viability of EC, U87 glioma cell line and human astrocytes exposed to camptothecin-
loaded SLN, free drug and SLN was assessed by using the AlamarBlue™ assay. The pink-
coloured formazan product was quantified by absorbance measurement (λ (excitation) = 530 
nm, λ (emission) = 590 nm) to detect conversion of the dye by mitochondrial dehydrogenases. 
This assay is based on the ability of mitochondrial dehydrogenase to cleave the tetrazolium 
rings of an MTT derivative [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] 
and to form formazan crystals which are impermeable to cell membranes, therefore resulting 
in its accumulation within living cells. Before performing the assay, a standard curve must be 
designed, to know the most suitable cell seeding concentration for the measurements to fall 
into the assay linear detection range. 100 μL of cell suspension at different cell 
concentrations were seeded into wells of 96-well tissue culture test plates. After 24h of 
culturing on a humidified incubator at 37ºC under and 5% CO2 atmosphere, 10% of the culture 
volume AlamarBlue™ assay were added to the cultures and the plate was incubated for 24 
hours at 37ºC, in the dark. And at each time point 2h, 4h and 24h the absorbance were 
measured. The results were analysed by plotting absorbance versus cell seeding density.  
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Then, cells were seeded on the most suitable cell densities and incubated during 24 hour. 
Then, the cells were put in the presence of different formulations (CPT solution, CPT-SLN and 
unloaded SLN). The SLN formulations were diluted in complete medium to appropriate 
concentration. For the camptothecin solution, camptothecin was dissolved in DMSO (1mg/mL) 
and afterwards diluted in complete medium to appropriate concentrations. After 24h of 
culturing on a humidified incubator at 37ºC under a 5% CO2 atmosphere, 10% of the culture 
volume AlamarBlue™ assay were added to the cultures and the plate was incubated at 37ºC, 
in the dark and metabolic cell activity was measured for the following 2–24 h. The 
absorbance was measured on the multiwall plate reader and was expressed as % of control 
Statistical Analysis 
Statistical analysis were performed using GraphPad Prism 4.0; GraphPad Software, San Diego, 
CA, USA. ANOVA were performed to compare two or multiple independent groups. Then, a 
multiple comparison test were used. Results are reported as mean ± standard deviation (SD) 
from a minimum of three independent experiments. When the group was significantly 
different, p˂0.01. 
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Chapter 4  
Results & Discussion 
In recent years, it has been clear that the BBB is more than a simple barrier. It is composed 
by a complex neurovascular unit and soluble factors, all these conditions can have an impact 
on the barrier integrity and function. Specifically, in pathological conditions such as brain 
tumor and Alzheimer’s disease where there are a loss of BBB characteristics. Even though, 
the most crucial limitation in diagnosis and treatment of these diseases is the unique and 
complicated environment imposed by BBB. So far, as BBB as a critical obstacle, there are not 
an effective treatment [7]. As a result, how the BBB could be influenced by various 
pathogenic or drug factors using different simultaneous studies of various cell types 
(astrocytes and EC) and fluid phase factors (adhesion molecules and proinflammatory 
factors), it can be an important solution to increase the minimal ingress through the BBB of 
potential anti-cancer drugs [15].  
In following decades, the in vitro model has become a powerful mainstay tool for studying all 
this alterations. Since, it has a simple structure, a controlled environment and it can be 
possible create different cell cultures configurations as well as study different parameters at 
the same time. However, at present, no in vitro model can faithfully reproduce all the 
properties and characteristics of the in vivo BBB.  
Thus, a semi-permeable plate filter BBB model using human EC has been improved. Firstly, it 
was performed an in vitro model using endothelial mouse cells and astrocytes cells, to 
improve laboratory skills and understand better the mechanisms involved on this static 
model. Then, different in vitro models using three different type of human cells were 
established and numerous parameters were studied, specifically to provide a system that 
could be used to assess the permeability of anti-cancer drugs (CPT drug) and study BBB 
functions and biological interactions. 
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4.1. Characterization of the in vitro mouse model  
To have a first contact on the in vitro models methodology, it was performed monocultures 
and co-cultures using primary mouse astrocytes cells and bEnd3 cell line. Li and co-
researchers [47] have been exploring the impact of different types mouse BBB cells and 
various basement membrane coatings can have on the barrier integrity. Regarding this work, 
it was tested two different endothelial initial concentrations to understand how the densities 
of the cells can influence its integrity during the time, Figure 4.1. On day 7, the endothelial 
monolayer achieved the highest TEER values at 0.9x105 cells/cm2 initial concentration. After, 
this day, the cells became senescent in both concentrations and TEER values decrease which 
indicates the loss of barrier integrity.  
Figure 4.1 TEER measurements in different cell mouse densities on monoculture. The resistance value 
(Ω×cm2) of an empty ﬁlter was subtracted from each measurement. Three measurements 
were taken per ﬁlter, and each culture condition was performed with triplicate ﬁlters to obtain average 
TEER and standard deviation. ANOVA showed no significant differences between 1.8 x 105 cells/cm2 and 
0.9 x 105 cells/cm2 TEER measurements over time. 
Moreover, it was study the methodology to establish co-cultures using primary rat astrocytes 
on the on the inverted side of the semi-permeable filter. Also, it was assessed its impact on 
the barrier integrity by immunocytochemistry using tight junction markers, permeability 
assays using an compound with low molecular weight and TEER measurements [data not 
shown]. The TEER values with astrocytes increase, however, do not showed significant 
differences, the same results to permeability assay.   
Consequently, these first study was important to establish laboratory techniques and 
different approaches that were applied to the following in vitro models. Also, it was an 
opportunity to explore this new concept while orders were taken and all laboratory material 
and equipment necessary arrived.  
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4.2. Characterization of the in vitro human BBB model on 
monoculture 
 
The hCMEC/D3 cell line shows a stable phenotype, expression of endothelial cell markers, 
tight junction molecules, chemokine receptors and ABC-transporters. Furthermore, the 
paracellular permeability is much lower compared to other cell lines. These characteristics 
make the hCMEC/D3 an interesting tool for permeability studies and a long-lasting source of 
human brain EC to test [15, 48, 54]. Moreover, it will be a better solution to use human cells, 
to mimic the BBB in vivo, than use mouse cells.  
To the purpose of endothelial human cells function as a barrier, it is essential that they 
create a confluent monolayer with tight junction between the EC [60]. First of all, it was 
used different cellular concentrations and it was analyzed its integrity by TEER 
measurements, monitoring it over the time in cell culture. The barrier model has TEER values 
ranged between 0.9–32 Ω/cm2. The highest TEER value was achieved with an initial 
4.6x10⁴cells/cm2 cell concentration and with 7 days of culture, Figure 4.2.  
 
Figure 4.2 TEER measurements in different cell human densities on monoculture. The resistance value 
(Ω×cm2) of an empty ﬁlter was subtracted from each measurement. Six measurements were taken per 
ﬁlter, and each culture condition was performed with triplicate ﬁlters to obtain average TEER and 
standard deviation. ANOVA showed differences of TEER values on 2nd day at 5 x 104 cells/cm2 versus 2.3 
x 104 cells/cm2 (*), at 4.6 x 104 cells/cm2 versus 2.3 x 104 cells/cm2 (**) and at 2.3 x 104 cells/cm2 versus 
1.15 x 104 cells/cm2 (*); on 4th day at 5 x 104 cells/cm2 versus 2.3 x 104 cells/cm2 (***), at 5 x 104 
cells/cm2 versus 1.15  x 104 cells/cm2 (*) and at 4.6 x 104 cells/cm2 versus 2.3 x 104 cells/cm2 (*); on 6th 
day at 5 x 104 cells/cm2 versus 1.15  x 104 cells/cm2 (***), at 4.6 x 104 cells/cm2 versus 2.3 x 104 
cells/cm2 (**), at 4.6 x 104 cells/cm2 versus 1.15  x 104 cells/cm2 (***); on 7th day at 5 x 104 cells/cm2 
versus 2.3 x 104 cells/cm2 (*), at 5 x 104 cells/cm2 versus 1.15  x 104 cells/cm2 (***), at 4.6 x 104 cells/cm2 
versus 2.3 x 104 cells/cm2 (**), at 4.6 x 104 cells/cm2 versus 1.15  x 104 cells/cm2 (****); on 8th day at 5 x 
104 cells/cm2 versus 1.15  x 104 cells/cm2 (**) and at 4.6 x 104 cells/cm2 versus 1.15  x 104 cells/cm2 (**); 
on 11th day at 5 x 104 cells/cm2 versus 1.15  x 104 cells/cm2 (*). At 4.6 x 104 cells/cm2 there are 
statistical significant differences (*) between the 7th day and 11th day. * (p≤0.05) indicates statistical 
significant differences; ** (p≤0.01) indicates very statistical significant differences; *** (p≤0.001) 
indicates extremely significant statistical differences and **** (p≤0.0001) indicates extremely significant 
statistical differences. 
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The TEER values obtained were lower than those usually obtained in vivo (1500-8000 Ωcm2). 
TEER values higher than 1000 Ωcm2 are really difficult to achieve on the in vitro cell culture 
model, specially for immortalized cell lines compared to primary cells. Nevertheless, the 
TEER values obtained are in agreement with recent publications, under static culture 
conditions the values are around 40 Ωcm2  [60, 61]. However, there are some strategies that 
can be used to increase TEER values, such as increasing hydrocortisone (anti-inflammatory 
steroid) concentration can influence the expression of TJ proteins and increase TEER values 
close to 300 Ωcm2 [62], added different cells types to mimicking the neurovascular unit or 
applied flow based shear stress, the TEER reported achieved 1000-1200 Ωcm2 [15, 48]. 
Moreover, on the last days, 8th and 11th, the TEER values are decreasing which indicates that 
the cells became senescent and the barrier is disrupted. As a result, besides the low TEER 
values, it was proven that the hCMEC/D3 monolayer do reflect an intact and functional 
barrier at 4.6 x 104 cells/cm2 as initial concentration. Furthermore, the TEER values are, in all 
experiences, very similar which indicates a reproducible approach to study the BBB. 
Besides the TEER analysis, the membrane integrity was evaluated by optical microscopy 
giemsa technique, Figure 4.3, and by observation of membrane markers, WGA-Alexa Fluor 
488, using immunocytochemistry technique, Figure 4.4. Both analysis were performed at 
different time points, on 2nd, 4th, 7th, 9th and using 4.6x104 cells/cm2 as initial concentration.  
Figure 4.3 Phase contrast microscopy observation of an endothelial-enriched human culture with 
giemsa staining grown on semi-permeable filters with 200x magnification. A. 2nd day. B. 4th day. C. 7th 
day. D. 9th day. Bar = 50 µm. 
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Figure 4.4 Immunofluorescence labeling endothelial-enriched culture with DAPI (nucleus dye) and Alexa 
Fluor-488 WGA (plasma membrane dye) grown on semi-permeable filters with 200x magnification. A-C. 
2nd day. D-F. 4th day. G-I. 7th day. J-L. 9th day. E. 11th day. Bar= 10 µm. 
Without a doubt, the images from both techniques showed, on initial stages - 2nd and 4th days, 
the presence of spaces with low cellular interactions, which indicates the normal cellular 
growth on semi-permeable filters. On the other hand, on last day, Figure 4.3-D and figure 
4.4-J to L, the cells present a random pattern known as “edge effect” and became 
senescence. Consequently, there are an alteration on barrier integrity which is in agreement 
with the decreasing of TEER values over the time. Finally, on 7th day, the cells form a 
monoculture with very few gaps and high cellular interactions indicating that this is the day 
where the cells form a confluent monolayer and the barrier maintains its integrity. However, 
it is necessary to study specific endothelial specific markers to analyze if barrier presents a 
highly restrictive barrier and also to study the localization of tight junction markers.  
Therefore, to guarantee the phenotype of this endothelial cell line, on the 7th day and using 
4.6x104 cells/cm2 as initial concentration, the expression of endothelial specific markers were 
analyzed by flow cytometry, Figure 4.5. Also, the expression of TJ proteins as well as 
adhesion junctions where analyzed by immunostaining, Figure 4.6. 
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Figure 4.5 Cellular gate and fluorescence histogram from hCMEC/D3 flow cytometry experiment using 
VE-Cadherin-FITC. [A] The dotted red line indicates the gate for individual hCMEC/D3 cells. Establishing 
this gate excludes debris (lower left) and aggregated cells (upper right) from analysis. [B] Gray tracks 
are negative controls, corresponding to staining in the absence of the antibody marker, while tracks in 
black are specific staining for the indicated adhesion marker. 
 
 
Figure 4.6 Immunofluorescence images. Immunofluorescence labeling endothelial-enriched culture with 
DAPI and A-C Occludin-Alexa Fluor 594; D-F Claudin-5-Alexa Fluor 488; G-I VE-Cadherin-FITC grown on 
semi-permeable filters at 200x magnification Bar=50 µm. J-L VE-Cadherin-FITC at 400x magnification on 
coverslip cell culture. 
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The three proteins tested are well characterized endothelial markers, VE-Cadherin is an 
adhesion junction marker present on the majority of EC and Occludin and Claudin-5 is 
expressed where a tight junction is established. For this reason, this three markers can be 
good indicators to evaluate the barrier of the in vitro model. However, occludin and claudin-
5 markers are important to guarantee EC phenotype and barrier integrity, this cell line 
showed lower expression of claudin-5 and occludin [63].  
Concerning to flow cytometry analysis around 44 % of the cells are expressing the endothelial 
specific marker. These are immortalized cells which had been submitted to some 
modifications which can influence the expression of some markers over the time in culture, 
however these values are consistent. By contrast, hCMEC/D3 cells were not stained by 
markers specific for other brain cells, specifically GFAP (astrocytes cells), which guarantee its 
phenotype [data not shown].  
Moreover, on Figure 4.6 – C and Figure 4.6 - F show a pure endothelial culture as occludin and 
claudin-5 staining can be noticed in the majority of all DAPI-stained cells, showing the TJ 
established. Also, on Figure 4.6 – G VE-Cadherin is expressed for all endothelial culture. 
However, on Figure 4.6 – L, VE-Cadherin on coverslip culture in higher magnification, it is 
more evident the endothelial monoculture well organized and continuous cell-cell borders, as 
well as very few gaps on the membrane filter. It seems that the semi permeable filter have 
an impact on the background of the image which is not visible when stained in coverslips.  
Also, the low expression of tight junction markers can be due to the lack of astrocytes on 
culture that are important to maintain BBB phenotype. The astrocytes produce different 
members of the Wnt family which increase the expression of junctional proteins. Even, on the 
endothelial medium were added different compounds, hydrocortisone and lithium chloride 
(Wnt/β-catenin signaling activator) [64], as well as bFGF that can enhance expression of 
junctional proteins [48]. These compounds could not be present on the same concentrations. 
Therefore, increasing or modulating these three compounds can influence the expression of 
tight junction markers and improve the growth of this cell line on the in vitro cellular model 
[48].  
Finally, it was performed permeability assays using three compounds with different MW. The 
compounds crossed the semi-permeable filter with different rates during 150 minutes, 
through the EC monolayer, Figure 4.7 – A, and through the “blank” filter i.e. the filter coated 
with rat tail collagen type I without any cellular barrier, Figure 4.7 – B. The FD4, FD40 and 
FD70 are used as a marker of paracellular permeability.  
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Figure 4.7 Permeability assay. Permeability experiment were taken at 7th day, FD4, FD40 and FD70 
crossed the endothelial barrier. [A] Through the cell monolayer. [B] Through the blank filter.  
Considering the “blank filter” permeability values, it is clear that it has an impact on the 
experiment, as initially 500 µg applied to the luminal side of the filter, 357 µg – 71%  FD4, 257 
µg – 51 % FD40 and 139 µg – 27% FD70 crossed to the abluminal side. It is also evident that the 
EC decrease this permeability, approximately only 120 µg – 24% for FD4, 56 µg – 11 % for FD40 
and 13ug – 2.56% for FD70 can be able to cross the endothelial barrier.  
As referred to apparent permeability the values are for FD4 is 15.3 ± 0.6x10-6   cm/s, for FD40 
is 6.9 ± 1.2x10-6 cm/s and for FD70 is 1.6 ± 0.2x10-6 cm/s, during the assay TEER values was 
found to remain constantly. These values are similar to published data, concerning to FD4 
compound, Ragnaill and co-researchers achieved values around 5.5x10-6 cm/s [60], Wekler 
group around 6x10-6 cm/s [54] and finally Forster and colleagues achieved higher permeability 
values around 13x10-6 cm/s [62]. In comparison with rat cells using the same compound, 
higher permeability values are achieved, the values are 16.3x10-6 cm/s. Finally, for bovine 
brain EC on monoculture the values are very similar, 7.2x10-6 cm/s to the human EC on 
monoculture [54]. 
These values showed that the in vitro BBB model on monoculture represents a highly 
restrictive barrier and the hCMEC/D3 cell line exhibits a higher paracellular resistance. So, it 
indicates that the model can be used to study CPT-SLN permeation. 
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4.3. The influence of different cells on the in vitro BBB model 
 
Recent studies have been shown that the increase of the complexity of the model can be 
improve the integrity and reproduce better the BBB in vivo. So, it is clear that perform co-
cultures with different cell types and various factors can be a good strategy to study better 
the BBB. In this way, it was added to the last model, primary astrocytes and a glioma cell line 
and both at the same time to study the impact on TEER resistance, paracellular permeability, 
expression of endothelial cell markers and endothelial surface. 
Before to perform the in vitro models set-up, it was analyzed the cellular growth until the 
confluence stage on cell culture flasks and on semi-permeable filters. Also, it was analyzed 
various published approaches where human cells were used or where it was used the same 
methodology. 
Concerning to EC co-cultured with the glioma cell line, it had been in consideration that on 
2nd day the EC are already seeded on the semi-permeable filter and expressing TEER values 
around 18 Ωcm2. The glioma cells were seeded on the bottom of the abluminal side based like 
reported for other researchers [65]. Mainly, the impact of the glioma on the EC is from the 
factors released on the cellular medium as recently Dwyer and co-researchers [66] showed. 
Thus, the glioma cell line was seeded the on 2nd day and co-cultured performed during the 
follow five days.   
Regarding to EC co-cultured with primary astrocytes, it has been in attention that primary 
astrocytes growth it is much lower than EC one, in order to leave them to establish without 
any environment interaction, these cells were seeded first. Astrocytes were seeded on the 
inverted side on the filter, as reported by [47] and [15], to create possible mechanical 
interactions which can influence the EC characteristics and develop an in vitro model more 
close that what happens in vivo. Then, to maintain the endothelial monoculture set-up, it 
was added the EC after the astrocytes are on semi-permeable filter. The initial astrocytes 
concentration, it not in agreement with other works mainly due to the cellular limitation and 
low growth. Finally, the co-cultures were maintained during the follow seven days.   
The last model, where it was used the three cell types, were established using the last ideas.  
Firstly, it was study the integrity barrier in the three different conditions by TEER 
measurements. To illustrate the main differences it was separate the three conditions in 
three independent graphs. Figure 4.8 refers to EC co-cultured with U87 glioma cell line. 
Figure 4.9 indicates the impact the astrocytes cells have on EC. And then, on figure 4.10 is 
possible analyze the TEER values differences between the three in vitro models purposed. 
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Figure 4.8 TEER measurements in co-culture, endothelial cells and U87 cell line. The resistance value 
(Ω×cm2) of an empty ﬁlter was subtracted from each measurement. Six measurements were taken per 
ﬁlter, and each culture condition was performed with triplicate ﬁlters to obtain average TEER and 
standard deviation. ANOVA showed differences of TEER values on 2nd day, at Endothelial cells versus 
U87 cell line (***); on 4th day at Endothelial cells versus U87 cell line (**); on day 7th day at Endothelial 
cells versus U87 cell line (****), Endothelial cells versus Endothelial cells + U87 cell line (**) and 
Endothelial cells + U87 cell line versus U87 cell line (**). At Endothelial cells there are statistical 
significant differences (*) between the 4th   day and 7th day. * (p≤0.05) indicates statistical significant 
differences; ** (p≤0.01) indicates very statistical significant differences; *** (p≤0.001) indicates 
extremely significant statistical differences and **** (p≤0.0001) indicates extremely significant 
statistical differences. 
 
Figure 4.9 TEER measurements in co-culture, endothelial cells and primary astrocytes cells. 
The resistance value (Ω×cm2) of an empty ﬁlter was subtracted from each 
measurement. Six measurements were taken per ﬁlter, and each culture condition was performed with 
triplicate ﬁlters to obtain average TEER and standard deviation. ANOVA showed differences of TEER 
values on 2nd day, at Endothelial cells versus astrocytes (**); on day 7th day at Endothelial cells versus 
Astrocytes (****), Endothelial cells + Astrocytes versus Astrocytes (***) and Endothelial cells + Astrocytes 
versus Endothelial Cells (*). At Endothelial cells there are statistical significant differences (*) between 
the 4th   day and 7th day. * (p≤0.05) indicates statistical significant differences; ** (p≤0.01) indicates 
very statistical significant differences; *** (p≤0.001) indicates extremely significant statistical 
differences and **** (p≤0.0001) indicates extremely significant statistical differences. 
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Figure 4.10 TEER measurements in endothelial cells cultured with U87 cell line and primary astrocytes 
cells. The resistance value (Ω×cm2) of an empty ﬁlter was subtracted from each 
measurement. Six measurements were taken per ﬁlter, and each culture condition was performed with 
triplicate ﬁlters to obtain average TEER and standard deviation. ANOVA showed differences of TEER 
values on 2nd day, at Endothelial cells versus Endothelial cells + Astrocytes + U87 cell line (*); on 7th day 
at Endothelial cells versus Astrocytes + Endothelial Cells (*), Endothelial cells versus U87 cell line (**) 
and Endothelial Cells versus Endothelial cells + Astrocytes + U87 cell line (***). At Endothelial cells there 
are statistical significant differences (*) between the 4th day and 7th day. * (p≤0.05) indicates statistical 
significant differences; ** (p≤0.01) indicates very statistical significant differences and *** (p≤0.001) 
indicates extremely significant statistical differences.  
Then, it was chosen FD4 molecule to perform permeability assays due to the high crossed flux 
on the endothelial monoculture, Figure 4.11.  
 
Figure 4.11 Permeability assay on 7th day. Permeability experiment using the FD4 molecule. [A] 
Through the different cell cultures, endothelial cells, U87 cell line and endothelial cells, endothelial 
cells and astrocytes and finally, endothelial cells, astrocytes and U87 cell line [B] Through the controls 
filters, U87 cell line and astrocytes, the blank filter without any cells and astrocytes. 
 48 
 
 
 
As expected, glioma cell line presence decreased TEER values and integrity barrier is 
affected, figure 4.8. The apparent permeability values for this cellular condition was 8.9 ± 
0.5x10-6 cm/s and around 14% FD4 crossed the cellular membrane. As said before, the FD4 
apparent permeability on the monoculture was 15.3 ± 0.6x10-6   cm/s. In comparison with 
reported works as [66], there are 2.5 fold augmentation of the FD40 apparent permeability to 
compared with the negative condition, the serum free media. However, in this study it was 
used only the conditioned medium. And in the model purposed, the glioma cells are seeded 
on the bottom which can influence the sample collect. For this reason, the permeability 
values with glioma cells presence are not so higher as has been expected, Figure 4.11.  
According to astrocytes effect, no significant differences were observed in TEER values 
between endothelial cells and EC co-cultured with human astrocytes, Figure 4.9. However, 
thus it has already been confirming by Poller and co-workers [67] and Weksler and co-
researchers [48], which indicates that this cell line is capable to form an tight barrier even 
without astrocytes cells. In contrast of Hatherell work [49] that showed significant difference 
to use astrocytes in co-culture with EC. The main reason for this opposite opinion can be the 
serum supplementation or the astrocytes cells used to be different.  
On permeability experiment seems that astrocytes alone do not influence the integrity of the 
barrier as well as the astrocytes co-cultured with EC, Figure 4.11. The apparent permeability 
was 7.6 ± 6.1x10-6 cm/s and around 18% FD4 crossed the barrier. Though, this results can be a 
consequence of the low initial cellular concentration that cannot be sufficient to influence 
EC.  
Finally, when comparing the in vitro model with three cells, it is clear that astrocytes are not 
able to reduce the U87 cell line effect on the TEER values, Figure 4.10. Also, in this 
condition, EC remain the model with higher TEER values. Concern to the permeability values, 
the apparent permeability was 10.5 ± 1.1x10-6 cm/s and around 16% FD4 crossed, Figure 4.11, 
which is in agreement with the TEER values decreasing. 
To understand better the impact the U87 cell line on the barrier, it was performed 
immunocytochemistry and flow cytometry analysis. In case of immunocytochemistry it was 
tested occludin, VE-cadherin and claudin-5. The images taken showed unspecific bound [data 
not shown]. On flow cytometry studies were tested VE-cadherin FITC, since VE-Cadherin plays 
an important rule on leukocyte extravasation, Figure 4.12. 
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Figure 4.12 Fluorescence histogram from hCMEC/D3 co-cultured with U87 cell line using VE-Cadherin-
FITC. Gray tracks are negative controls, corresponding to staining in the absence of the antibody 
marker, while tracks in black are specific staining for the indicated adhesion marker. 
As expected the VE-Cadherin expression is affected [66], which indicates the VE-Cadherin 
mediated cell-cell junctions alteration during the time exposed to U87 cell line released 
factors. However, tested at different time points it will be necessary to proven its remodeling 
during the time exposed to the inflammatory factors released by U87 cell line. Moreover, it 
was analyzed endothelial and astrocyte surface by SEM, Figure 4.13, 4.14 and 4.15. 
 
 
Figure 4.13 SEM images of surface endothelial cells co-cultured with astrocytes and U87 cell line on 7th 
day. [A] Endothelial cells with astrocytes at 250 x magnification. [B] Endothelial cells with astrocytes at 
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1000 x magnification. [C] Endothelial cells on co culture with U87 cell line at 250 x magnification.  [D] 
Endothelial cells on co culture with U87 cell line at 1000 x magnification. 
 
  
Figure 4.14 SEM images of endothelial cells surface co cultured with astrocytes and U87 cell line in on 
7th day. [A] Endothelial cells with astrocytes and U87 cell line at 250 x magnification. [B] Endothelial 
cells with astrocytes and U87 cell line at 1000 x magnification. 
 
 
 
 51 
 
 
Figure 4.15  SEM images of endothelial cells, astrocytes and U87 cell line in culture on 7th day. [A] 
Astrocytes surface co-cultured with endothelial cells seeded on the semi-permeable filter coated before 
with Geltrex at 3500x magnification. [B] Astrocytes surface co-cultured with endothelial cells seeded on 
the semi-permeable filter coated before with Geltrex at 5000x magnification. [C] Endothelial cells 
surface co-cultured with astrocytes at 5000x magnification. [D] Endothelial cells surface co-cultured 
with astrocytes and U87 cell line at 5000x magnification. 
In agreement with last results, Figure 4.13–A and B and Figure 4.15-C clearly illustrates the 
growth of a confluent endothelial layer. The EC form a confluent monolayer with adjacent 
growth, with direct cellular interaction which promotes a highly restrictive barrier.  
On the other hand, U87 cell line changes cell morphology, Figure 4.13 – C and D, and TJ can 
be affected and damaged. In Figure 4.15-D it is possible analyze the semi-permeable plate 
filter and the membrane porous. Lastly, the EC co-cultured with astrocytes and U87 cell line 
are not differences in comparison with EC co-cultured with U87 cell line, Figure 4.14. Where 
continuous to exist a flattening of cell shape.  
In last results, it was not demonstrated any influence of astrocytes on the in vitro model by 
the soluble factors that are under normal physiological conditions are released. Hatherel and 
co-researchers [49] showed that this specific cell line responds better to astrocyte contact 
rather than the soluble factors released to the astrocytes, which it is happens in vivo. Where 
astrocytes are closely to EC in the NVU. Other studies has the same conclusion, that 
astrocytes end-feet can crossed the semi-permeable filter and making contact with EC [68]. 
Figure 4.15-A and B showed that astrocytes have a key feature on mechanical interactions, 
since it seems that astrocytes long end-feet will cross the membrane for the luminal side.  
Although, more studies will be need to demonstrate this interaction in vitro, for example 
using transmission electron microscopy.  
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4.4. Nanoparticles characterization 
 
To nanoparticles can achieve easily the brain and cross the BBB is necessary an average size 
around 200 nm. Several parameters of the production method can alter the size likewise the 
time of stirring, time of sonication, sonication intensity and the temperature during the 
process. Based on work of Martins and co-researchers [57], it was optimized the production 
conditions to have a reproducible samples before the studies of nanoparticle interaction with 
cells [data not shown]. Also, experiments with animal models suggest that small (<200 nm), 
neutral or slightly negatively charged particles can move through tumour tissue [35]. 
Comparing, CPT average size values using both techniques, there are very similar. According 
to laser diffraction technique, CPT loading had no marked influence on the SLN size and both 
loaded and empty SLN presented particle median size (Dv50) around 0.200 µm, Figure 4.16, 
suitable for cell membrane passage and uptake under normal physiological conditions  (mean 
Dv50 for empty SLN was 0.194 μm ± 0.015 and for SLN-CPT was 0.193 μm ± 0.012). The 
particle size range is represented as mean Dv90 and mean Dv10, which where respectively 
0.506 μm ± 0.139 and 0.086 μm ± 0.005 for empty SLN, 0.772 μm ± 0.128 and 0.087 μm ± 
0.005 for SLN-CPT. PI values obtained were lower than 0.2 for all nanoformulations, 
suggesting that the nanoparticles were in a state of acceptable monodispersity distribution, 
with low variability and no aggregation.  
 
Figure 4.16 Volume density (%) analysis of Empty and CPT-loaded SLN particle size. Particle size was 
measured using the laser diffraction particle size analyzer (Malvern Mastersizer 3000, Malvern 
Instrument, Ltd. It represents at least three independent samples of each sample condition. 
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SLN also present a negative charge with zeta potential values of -21.27 ± 4.95 mV for empty 
SLN and -27.14 ± 5.68 for SLN-CPT which indicates a good nanoparticles repulsion and it is 
avoid nanoparticles agglomeration. Moreover, the drug incorporation seems not affect the 
nanoparticle charge. Also, the slightly negative charge is favorable to the brain uptake and 
can be safely used as colloidal drug delivery systems for brain targeting [35]. 
Before, to calculate the association efficiency it was necessary tested the method validated 
by Martins and co-researchers [56] by a calibrate curve to correlate the concentration of CPT 
present on the SLN formulation, Figure 4.17. 
 
 
Figure 4.17 Calibration curve to extrapolate CPT concentration values using HPLC method. 
 
Then, it was analyzed the association efficiency using two different methods. Lipid 
nanoparticles are known to be suitable systems for drug incorporation. Using as Martins and 
co-researchers [35], the method indirect to determine association efficiency of CPT drug the 
values obtained were around 98% which indicates a high encapsulation. However, other 
method were performed to validate the last ones and the values were complete different. In 
this case, the values obtained were around 11%. As a matter of fact that in the first 
methodology, the free drug were retained on the centrifuged membrane and it was not 
solubilized with the water. However, more studies like release studies need to be done to 
guarantee these association efficiency values.  
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4.5. In vitro studies 
 
Before to perform the viability analysis, it was tested different cellular concentrations and 
the absorbance were tested at different time points on EC, on glioma cell line and on primary 
astrocytes, Figure 4.18. Mainly, to understand which is the best concentration and time in 
culture to perform the nanoparticles-cellular studies.  
EC and glioma cells have the same cell concentration density, 200000 cells/mL and it is the 2 
hours curve that presents a linear curve, which indicates the best option to correlate the 
nanoparticles viability values.  However, when astrocytes values were analyzed, it was 
difficult to have differences between the time and a good correlation, due to the low cell 
proliferation and cell quantities.  Besides, this problems it was choose 24 hours and 20000 
cellular initial concentration to perform the follow studies.  
 
Figure 4.18 Reduction of Alarmar blue reagent on endothelial cells, on glioma cells and primary 
astrocytes.  The symbols indicates 2h of incubation;  indicates 4h of incubation and 
indicates 24h of incubation.  
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Figure 4.19 shows the viability assays results using CPT free drug, SLN, CPT-SLN and as 
control it was used untreated cells. Firstly, the cells were seeded on the 96 well plate and 
incubated during 24 hours. Then, different conditions were tested and controls were 
established at the same time. On the next day, it was added 10% of Alarmar Blue assay in the 
three different cells types and in all conditions. Finally, the absorbance were measured and 
viability results were calculated.  
 
 
Figure 4.19 Cellular viability of hCMEC/D3, human astrocytes and U87 cell line using the Alamar Blue 
Cell Viability Assay Reagent. Data is expressed as percentage of AlamarBlue reduction and represents 
the average of at least six independent samples. * (p≤0.05) indicates statistical significant differences; 
** (p≤0.01) indicates very statistical significant differences and *** (p≤0.001) indicates extremely 
significant statistical differences. 
 
In the three cellular conditions the unloaded SLN showed low cytotoxicity and presents higher 
cytotoxicity when CPT was incorporated in SLN. In the three cases, there are cytotoxicity 
associated to the free drug, however when it is loaded in the SLN this cytotoxicity is 
 56 
 
 
 
prevented as it was expected. There are cytotoxicity associated to the unloaded SLN 
comparing to the untreated cells which can be the excipients used on the SLN matrix can 
inhibit the activity of the cells.  
The hCMEC/D3 viability values of CPT formulations showed higher potency as compared to 
the free CPT in solution.  Otherwise, viability results revealed a similar cytotoxicity to CPT-
SLN and the free drug in solution. Also, it is happens with astrocytes viability results.  
Comparing U87 cell line with EC with, CPT-SLN presents high cytotoxicity. This enhanced 
cytotoxicity of CPT-SLN can be explained by the fact that CPT-SLN can deliver more 
consistently. And, also, can be related to a higher uptake of camptothecin when incorporated 
in SLN by U87 cell line which is desired for drug efficacy in tumor brains. 
Concerning to astrocytes, there are cytotoxicity associated to the SLN-CPT similar to the free 
drug in solution which can be explain by the cellular limitation and for the high incubation 
time, 24h. In order to have accurate values, it is needed to test a high initial concentration 
and leave them to establish for more days in the 96 well plate culture. 
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Chapter 5  
Conclusion  
Recently, the interest on brain diseases drugs has been increased. But, the translational to 
the industry remain do not happen. Principally, it is due to the difficulty to cross the BBB and 
the low understand in all mechanisms and interactions involved in this barrier. So the study of 
this barrier need to be the first step in the study of new drugs. In case of brain tumors there 
is no effective treatment. Even though, there are different drugs to minimize the symptoms, 
the real treatment is far. However, using drug loaded into nanoparticles, it is possible 
increase effective treatment and reduce side effects.  
Taking this premises, it was purposed an in vitro BBB model and different techniques were 
applied. The monoculture model achieved on the 7th day the higher TEER values and with 
4.6x10⁴cells/cm2 as initial concentration, around 32 Ωcm2. Also, immunocytochemistry using 
membrane markers and optical microscopy staining with GIEMSA at different days showed the 
monolayer growth and the cellular senescence on the last day. Moreover, at 7 day the 
monolayer presents a confluent monolayer. Flow cytometry and immunocytochemistry using 
endothelial specific markers revealed the endothelial phenotype and the confluent monolayer 
on 7th day. Also, the permeability assay showed the highly restrictive barrier, since the only 
24% for FD4, 11 % for FD40 and 2.56% for FD70 can be able to cross the endothelial barrier. 
When, other factors were added to the in vitro model, there are changes on the TEER values. 
U87 cell line co-cultured with EC decreased TEER values around 20 Ωcm2 on 7th day, mainly by 
the barrier disrupted. Astrocytes co-cultured with EC decreased TEER values to values around 
25 Ωcm2, on 7th day because of the cellular limitation. Also, on the triple co-cultured system 
the TEER values are lower when compared with the endothelial cell monoculture. 
Concerning, to permeability analysis all conditions present lower apparent permeability 
values than on the monoculture condition. In case of U87 cell line co-cultures with EC the 
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apparent permeability is around 8.9 ± 0.5x10-6 cm/s, in astrocytes co-cultured with EC 7.6 ± 
6.1x10-6 cm/s and in the triple co-cultured model is 10.5 ± 1.1x10-6 cm/s.  
The low permeability of the U87 cell line co-culture are not in agreement with SEM images, 
where tight junctions are cleared disrupted, so it can be a problem of the U87 cell line were 
seeded on the bottom of the abluminal side. Moreover, SEM images revealed the importance 
of the mechanical astrocytes influence on the BBB structure and mechanisms.  
hCMEC/D3 cell line is the most promising immortalized cell line, since it presents the most 
properties existed in vivo. Moreover, the EC co-cultured with astrocytoma cell line clear 
maintains its reproducibility and can be tested as in vitro pathological model that could be 
used as tool to screening different drugs. With exception to the models where it was included 
astrocytes, the application of a robustness protocol it is possible to guarantee its 
reproducibility.  
Also, in this study it was produced and characterized CPT-SLN, based on the last work done 
for our group.  Multivariate analysis revealed that CPT-SLN has a stable structure, mainly 
because of the mean size around 200 nm and low size distribution.  
In vitro viability study on EC revealed that CPT cytotoxicity is reduced when drug is 
incorporated in the SLN system. Moreover, the cytotoxicity of CPT-SLN has higher potency on 
when compared the same effect on EC, which indicates the therapeutic efficiency.  
Thus, SLN can be a promising carrier since the problems of solubility, toxicity and stability 
are reduced in comparison with the free drug in solution. The values are promising to 
perform permeability analysis.  
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Chapter 6  
Future work 
In future, it will be interesting the use of the in vitro model for other team. Mainly, to 
discuss the laboratory problems or difficulties which can improve, the in vitro model 
establishment.  
Then, the addition of other cells such as pericytes or neurons, can improve the in vitro BBB 
model complexity and can influence nanoparticles permeation and cellular interactions. To 
avoid limitation of astrocytes cellular number, it can be a good solution use immortalized 
astrocytes.  
According to nanoparticles, it will be possible decrease toxicity effects by functionalization, 
using a specific or overexpressed BBB receptor for example the transferrin receptor. It will be 
necessary to study the drug release to have a conclusion of the association efficiency value. 
Finally, it will be interesting to perform nanoparticle permeation using the in vitro model 
purposed.  
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